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ABSTRACT
A number of boron neutron capture therapy (BNCT) clinical trials are currently underway
around the world. Due to the small number of patients at each of the individual centers, it
is desirable to pool the clinical data from each into one patient database. Before this can
be done, a number of differences between the clinical centers must be evaluated. The
patients treated at the BNCT centers at Brookhaven National Laboratory and that at
Harvard-MIT will be evaluated as a start to the ultimate pooling of all the BNCT centers.
One difference involves the difference between the normal tissue composition definition
between the institutions. In particular, the difference in weight percent of 4N must be
evaluated. This particular component of tissue is of importance due to the dose to tissue
resulting from the 4N(n,p)l C reaction. The difference between the 1.8% '4N
composition used at BNL and the 2.2% used at MIT has a negligible effect on the total
dose. Most importantly, differences in dosimetry techniques between the different
centers must be computed. Once these differences are quantified, the patients can be
pooled, and a better estimate of the normal brain tolerance to BNCT can be determined.
The thermal neutron doses calculated from thermal flux measurements are 8% lower
when measured by MIT, the gamma dose measurements are 26% lower, and the in-air
fast neutron measurements are 27% lower in the same beam. The endpoint used for the
tolerance of normal brain to BNCT is somnolence syndrome. A 50% somnolence
response can be seen at 5.5 Gy-Eq.
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Title: Associate Professor of Nuclear Engineering and Rasmussen Professor of Nuclear
Engineering
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I. Background
1. BNCT
Boron neutron capture therapy (BNCT) is an experimental binary radiation treatment
modality currently being tested against types of cancer that have proven difficult to treat
by traditional means, such as the primary brain tumor glioblastoma multiforme (GBM).
BNCT relies on the thermal neutron interaction with 10B, which has a high thermal
neutron capture cross-section. A tumor-selective boron-labeled compound is
administered to the patient, followed by neutron irradiation. When the °B nucleus
interacts with a thermal neutron, it emits an alpha particle and a 7Li ion through the
'(B(n,a)7 Li reaction. These emitted particles both have very short path lengths in tissue
(about 9m for the alpha particles and about 5m for the 7Li [1]); these distances are
about the same as the diameter of a cell. Because of this, the damage caused by the
energy deposition of the alpha particles will occur close to the location of the original 10B
interaction.
BNCT treatment of tumors is quite different than conventional radiotherapy treatment
of tumors. The photon beams used for conventional radiotherapy are targeted to the
tumor. They are sharply collimated, and can be shaped according to the best treatment
plan. For instance, in gamma knife treatment, multiple pencil beams are used, and they
all cross at the tumor, which allows for maximum dose to be administered to the tumor
tissue, while sparing the normal tissue. Therefore, in conventional radiotherapy, normal
tissue sparing comes from beam geometry and collimation. In BNCT, low-energy
neutrons are needed for the neutron capture reaction in boron. These low-energy
neutrons scatter once they enter tissue. Because of this, a dose is administered to the
entire treatment region. Both the tumor and a considerable volume of surrounding
normal tissue are exposed to neutrons, and there is always a non-specific background
beam dose administered to the normal tissues. If capture compounds with good
selectivity are used, then the dose to normal tissue is less than the dose to tumor tissue.
Thus, in BNCT, normal tissue sparing comes from selective accumulation of boron in the
tumor, and BNCT can be used to destroy tumor cells that microscopically infiltrate into
normal tissues. BNCT should be thought of as a tumor-targeting therapy at the cellular
9
level. With suitable compounds and neutron beams, BNCT can, in principle, control
cancer in large tissue volumes such as whole brain without unacceptable damage to
normal brain. BNCT can also, in principle, kill individual tumor cells while sparing the
adjacent normal cells. Average therapeutic ratios of about 3 to 4 can be calculated for
BNCT using the currently available capture compound boronophenylalanine (BPA).
In clinical trials, BNCT has mainly been used to treat malignant gliomas, particularly
glioblastoma multiforme (GBM). GBM accounts for about 80% of all malignant
gliomas, and is one of the most intractable brain tumors. Despite conventional treatments
(surgery, chemotherapy, traditional radiotherapy), patients with GBM have a median
survival time of 9 to 10 months, and a 5-year survival rate of <5% [2]. GBM is a highly
invasive tumor, with tumor cells infiltrating deeply into the surrounding brain tissue,
creating microscopic islands of tumor cells set apart from the main tumor. These
infiltrating tumor cells cannot be killed by conventional radiotherapy because a dose
large enough to kill them would be administered to normal brain tissue as well, and such
a high dose could cause brain damage. Because of this, BNCT is being investigated as an
alternative means of treating these types of tumors. Given sufficient tumor-selectivity of
the boron-containing compounds, BNCT would have the ability to treat these infiltrating
tumor cells without causing significant damage to the surrounding normal brain tissue by
allowing for a much lower total dose of radiation to be administered to the normal brain.
2. BNCT Clinical Trials
Table 1 lists the details of the major clinical trials of BNCT around the world [3].
The first clinical trial of BNCT for patients with GBM began in 1951 at Brookhaven
National Laboratory (BNL), in the Brookhaven Graphite Research Reactor (BGRR).
Over the next 8 years, three series of patients were irradiated there. The BGRR was
originally built as a physics facility and therefore was not ideal for BNCT (it had no
medical facility, no treatment room, no beam shutter, etc.). Results from clinical trials
run at this facility were unsuccessful. The lack of success in these clinical trials was due
mainly to problems with the boron compounds available at the time. These compounds
did not exhibit tumor selectivity; they instead relied on the blood brain barrier to keep '°B
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out of the normal brain tissue. This led to high concentrations of '°B in the blood, which
resulted in damage to the brain and skin. In the mid 1950's the Brookhaven Medical
Research Reactor (BMRR) was designed and constructed primarily for use in BNCT.
The BMRR became operational in 1959. Over the following two years, a number of
patients with brain tumors received BNCT at the BMRR [1]. During these trials, patients
were given one of a number of boron-carrying compounds and irradiated with a thermal
neutron beam.
At the same time (between 1959 and 1961), patients were also being treated with
BNCT at the Massachusetts Institute of Technology reactor (MITR). During these trials,
a number of different boron compounds and thermal neutrons were used in combination
with a variety of surgical interventions. Results from both the BNL and MIT studies
were disappointing and all clinical trials of BNCT in the United States were halted in
1961. The disappointing results arose from two primary causes. The first was that the
thermal neutron beams did not penetrate very far into tissue. Because of this, there was
inadequate thermal neutron fluence at depth (i.e., if the tumors were deep-seated enough),
and some damage was also observed in the patients' skin. Secondly, low tumor to blood
ratios were achieved with the boron-containing compounds available at the time. Both of
these problems led to damage to the scalp and to the blood vessels in the brain.
The late Hiroshi Hatanaka began BNCT trials in Japan in 1968 at the Hitachi Training
Reactor (HTR). Prior to this, Hatanaka had worked with Dr. William Sweet, who was
pioneering much of the U.S. BNCT research, at Massachusetts General Hospital where
he had learned surgical intraoperative procedures for BNCT. Over the course of the next
33 years (between August 1968 and July 2001), 183 patients with malignant brain tumors
were treated with BNCT using a boron "cluster" compound Na 2B1 2H SH, or BSH, and
thermal neutron irradiation at 6 different reactors in Japan (however 10 patients since
1998 have been treated with epithermal neutrons under a new protocol). The tumor-to-
blood boron concentration ratio was typically around 1.2-1.69 for BSH in these trials [4].
Results from these patients were more promising than those previously treated in the
United States. Out of 105 patients, 29 with Grade 2, Grade 3, or Grade 4 gliomas
survived for longer than 3 years [4].
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BNCT reemerged in the United States after improvements were made in both boron
compounds and neutrons beams in the late 1980s. At this point, higher-energy
epithermal neutron beams (0.5 eV < E < 10 keV) were created at both the BMRR and the
MITR. These higher energy neutrons are moderated as the beam penetrates into tissue to
become low-energy thermal neutrons, which can then be captured by the boron-
containing compound in tumor tissue. This allows for tumors that are found deeper in the
brain to be treated with BNCT, and it decreases the risk of damage to skin, since the
thermal neutron flux is low at the surface in contrast to the thermal neutron beams where
the highest flux is at the skin.
In 1997, a Phase I trial for BNCT began in Petten, the Netherlands. Three years later,
another trial began in the Czech Republic. These two studies treat brain tumors using the
boron compound, sodium borocaptate [5]. Two other European trials, one in Finland and
one in Sweden, have been treating GBM patients using the boron compound
boronophenylalanine (BPA). All of the European studies have used epithermal neutron
beams. A detailed review of all BNCT clinical trials is beyond scope of this thesis.
The most recent clinical trial at BNL ran from 1994 until 1999. During this time, 53
patients were treated with BNCT [2, 6]. Over the course of those 5 years, a number of
changes in the treatment occurred. One change was simply prescribed by the definition
of the clinical study. The clinical trial was a dose-escalating study, and therefore both the
peak brain dose and the whole-brain average dose received by the patients was increased
over time. Also, the treatment at BNL changed from a one-field treatment to a two-field
treatment, and ultimately to a three-field treatment. Increasing the number of fields
allowed for more uniform dose delivery to tumor and target volumes (target volume was
defined as tumor volume plus a 2 cm margin around the tumor). Combining fields also
allows for a higher peak in the target region, and lower doses to normal tissue.
Additionally, a new collimator was created (the old collimator was 8 cm in diameter with
a 13.1 cm thickness, and the new collimator was 12 cm in diameter with a 20.7 cm
thickness), and the fuel rods in the reactor were rearranged in 1996. This caused
desirable changes in neutron and photon flux intensities.
In 1994, epithermal neutron BNCT irradiation of peripheral metastatic melanoma
were initiated at the MIT reactor (MITR), and this was followed by the brain tumor
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clinical trial at Harvard-MIT begun in 1996 to evaluate normal tissue tolerance as well as
tumor response. Between that time and May 1999, 22 patients were treated with BNCT
using the MIT M67 beam. All of these patients were treated for either GBM or
melanoma. As with the BNL trial, the number of fields used varied from one to three
over the three years of the clinical trial, resulting in a progressive increase in both the
peak dose and the whole-brain average dose. Harvard-MIT used the compound BPA, at
doses of either 250mg/kg over the course of 1 hour, 300mg/kg over 1.5 hours, or
350mg/kg over 1.5-2 hours. The M67 epithermal neutron beam was used at MIT for the
22-patient phase-I trial, and it was equipped with a 15cm collimator [7]. This beam was
located underneath the MITR, and the beam was directed downwards from the ceiling.
Due to limitations in the M67 beam (such as low flux of epithermal neutrons and patient
positioning difficulties), in 2001 a new fission converter beam (FCB) was constructed at
MIT. This new beam has higher neutron intensity and less contamination from fast
neutrons, slow neutrons, and photons [24]. Since this beam was built, 6 patients have
been irradiated in a Phase I/II trial of BNCT with epithermal neutrons there. These
patients are not included in this thesis because the data have not yet been published and
the clinical records are unavailable at this time.
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Table 1: Description of BNCT clinical trials around the world over the past 40 years [3]
Infusion Peak Brain Ave. Brain
10B Infusion Amount Ave. BBC' Dose Dose
Facility # of Patients Compound Time (mg/kg) (g 'l°B/g) (Gy-Eq) (Gy-Eq)
HTR,
MuITR,
JRR, KUR
Japan
The
183
(1968-
present)
26
(1997-
Netherlands present)
LVR-15
Rez
BSH Ihr 100 -20-30
100
BSH mg/kg/min 100 303
5
Czech Rep. (2001 -pres.)
BMRR
BSH 1 hr 100 -20-30
53
(1994-1999) BPA 2 hr 250-330 12-16
225
MIT, USA (1996-1999)
MITR-II,
BPA 1-1.5 hr 250-350 10-12
6
MIT, USA (2001-pres.)
Studsvik
BPA 1.5 hr
17 (30)6
Sweden (2001-pres.)
18
BPA
350 -15 7.0-7.7 6.90-7.80
24
(range: 15-
6 hr 900 34) 7.3-15.5 3.3-6.1
Fir I (1999-pres.)
Finland protocol P-01
3
Fir I
BPA 2 hr 290-400 12-15
(2001 -pres)7
Finland protocol P-03 BPA 2 hr 290 12-15
' BBC = blood boron concentration during the irradiation. 2 "B physical dose component dose to a
point 2 cm deeper than the air-filled tumor cavity. 3 4 fractions, each with a BSH infusion, 100 mg/kg the
first day, enough to keep the average blood concentration at 30 mg 'B/g during treatment on days 2-4. 4
10B physical dose component at the depth of the thermal neutron fluence maximum. 5 Includes 2
intracranial melanomas. 6 J. Capala, unpublished, personal communication with J. Coderre. 7 Retreatment
protocol for recurrent glioblastoma.
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15 Gy2
8.6-
11.4Gy 4
o0B
component
NA
NA
Brookhaven,
USA
MITR-II,
M67
< 14.2 <2
FCB
8.4-14.8 1.8-8.5
8.7-16.4 3.0-7.4
8-13.5
3-6
<7
<8
2-3
<6
3. Boron compounds and radiobiology
Over the years, a number of different compounds have been developed which show
preferential accumulation in tumors, though only two of these have reached the stage of
BNCT clinical trial: p-boronophenylalanine fructose (BPA-F, or simply BPA) and
sulfhydryl borane (BSH). BPA was first synthesized in the late 1950s for BNCT, but was
initially set aside due to the fact that it penetrates the blood-brain barrier, which at the
time was seen as a significant disadvantage. BPA was later used for treatment of
melanomas due to its structural similarity to melanin precursors [8]. In biodistribution
studies, BPA was found to selectively accumulate in rat 9L gliosarcomas [9]. While the
brain-to-blood boron concentration ratio was approximately 1, the tumor-to-blood/brain
boron concentration ratios were found to be closer to 3:1 or 4:1 [13]. This is most likely
due to elevated transport of amino acids at the tumor cell membranes [11]. Using ion
microscopy, intracellular boron was found to be uniformly distributed across the
cytoplasm and the nucleus in vitro and in implanted 9L brain tumors in rats injected with
BPA. The boron concentration in tumor clusters infiltrating the normal brain was found
to be about 50% of that in the main tumor for the BPA administration protocol that was
used [12]. BPA-based BNCT produced long-term control of over 90% of rats having
implanted 9L brain tumors [13].
As opposed to BPA, BSH does not cross the blood-brain barrier. It is able to
accumulate in tumors due to the fact that blood vessels in intracranial tumors lack a
properly functioning blood-brain barrier. Animal models showed a tumor to blood boron
concentration ratio of about 0.5:1 to 1:1 [14], but this ratio has been found to be
somewhat higher in human GBM patients. Hatanaka and Nakagawa have found a tumor-
to-blood boron concentration ratio of about 2:1 at 17.5 hours after the end of the
compound infusion in 39 patients, and four European centers showed ratios of about
1.3:1 to 2:1 [15].
Currently, BSH is mainly used in the Japanese trials, as well as a few of the European
trials. BPA was the compound used during the BNL trials and was used at the Harvard-
MIT trials, as well as in trials in Sweden. Patients treated with doses of 250 mg BPA/kg
at BNL showed no signs of toxicity after a 2-hour infusion [16], and in fact levels up to
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350mg BPA/kg have been administered to patients in the Harvard-MIT trials with a 1.5-
hour infusion time [7]. In Sweden, doses up to 900mg/kg administered over 6 hours,
resulting in average blood-boron concentrations of 24gtg/g at the time of irradiation, have
been administered to patients during a 6-hour infusion with no toxicity [17]. Both BPA
and BSH are administered to the patient intravenously. Using subcellular secondary ion
mass spectrometry (SIMS) on human glioblastoma cells incubated in vitro with l°B-
labeled BPA-F or l"B-labeled BSH, or both, intracellular levels of l°B from BPA-F were
found to nearly double between 1 h and 6 h incubations, with a 3:1 intracellular to
nutrient medium partitioning, while intracellular levels of BSH remained essentially
unchanged in both single- and mixed-drug treatments [18].
The total radiation dose received by a BNCT patient is comprised of several different
components; this is due in part to beam contaminants (photons), different neutron
interactions that occur in tissue (protons from the 14N(n,p)14C reaction and photons from
neutron capture in tissue hydrogen, the 'H(n,y)2 H reaction), and differences in the
distribution patterns of the boron compounds, as described above. Therefore, the total
dose is made up of a thermal neutron component, a fast neutron component, a gamma
component, and a boron component. To sum all these together requires expressing each
in a "photon-equivalent" unit to make it possible to compare against conventional photon
irradiation. To do this, relative biological effectiveness (RBE) factors must be applied to
each component. The RBE for each dose component has been determined
experimentally [14]. Typically, the RBE of a given type of radiation is due only to the
radiation's linear energy transfer (LET). In the case of the boron dose component in
BNCT, this is not true; the biological effect of boron also depends on which compound is
being used (i.e., specific microscopic distribution characteristics of the boron compound
must be taken into account). Because of this, instead of RBE, the term compound
biological effectiveness (CBE) factor is used. A "beam RBE" can be determined in the
absence of boron-10 by comparing a neutron beam dose with an X-ray dose sufficient to
produce an isoeffect. Once this beam RBE has been determined, the boron CBE can be
determined. Additionally, the individual fast and thermal neutron RBE factors can be
determined once the beam RBE has been determined. For each tissue and each boron
compound, the RBE and CBE factors can be determined using appropriate normal tissue
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irradiation models and comparing the x-ray dose, the neutron-only dose, and the neutron
plus boron dose required to produce an isoeffect [14]. Once each of the RBE factors has
been determined, they can be multiplied by their corresponding dose components and
summed together to obtain a total weighted dose, in units of gray-equivalent (Gy-Eq).
4. BNCT Treatment Planning
There are two primary treatment planning software programs available for BNCT.
Since this thesis focuses mainly on combining clinical data from the BNL and Harvard-
MIT programs and the differences in dosimetry and treatment plans between these
centers, discussion of treatment planning software will be limited to those used at these
two facilities: namely, Radiation Treatment Planning Environment (RTPE), as well as
some mention of its successor, Simulation Environment for Radiotherapy Applications
(SERA), both of which were used at BNL, and MacNCTPlan/NCTPlan, which is used at
MIT. RTPE and SERA were developed by a collaboration of the Idaho National
Engineering Laboratory (INEL) and the computer science department at Montana State
University [1.9], and were used by the BNCT group at BNL. The BNCT group in
Sweden is also currently using SERA. MacNCTPlan and NCTPlan were developed and
used by the BNCT group at MIT. These programs all rely on Monte Carlo codes to
transport particles through tissue. However, beyond this basic similarity, there are a
number of other differences in the software programs, and these differences may give rise
to differences in patient treatment plans. Therefore a description of the main
characteristics of each program is necessary for a complete comparison of clinical trials
at different institutions.
Before BNCT treatment planning software was developed, scientists determined that
a Monte Carlo (MC) code would be the most useful tool to use in creating a patient
treatment plan. In conventional MC codes, it is difficult to obtain the necessary detailed
edits for BNCT. While volume-integrated results are typically obtained automatically
with most MC codes, special edits must be performed to obtain the necessary output for
BNCT, such as dose volume histograms and isodose contours. Additionally, the patient
geometry would need to be modeled by hand for use in MCNP, instead of being able to
17
utilize CT or MRI scans. This would result in a significant increase in total treatment
planning time, due to the time it would take to create the special edits and then the extra
time it would take to run enough particles for statistical significance. This led to the
development of BNCT_edit, which is based on a Monte Carlo code called Raffle. Raffle
was developed at the Idaho National Engineering Laboratory (INEL) in the 1970's, and
in the 1980's it was extended to incorporate the most recent Evaluated Neutron Data File
(ENDF-V), resulting in Raffle V. By the 1990's, BNCT_edit was replaced with
BNCT_rtpe, which was first used in the BNL BNCT clinical trials in 1994 [19]. This
program is more commonly referred to as Radiation Treatment Planning Environment, or
RTPE. Contained in this program is the particle transport code called radiation transport
in tissue by Monte Carlo (better known as rtt_MC), which is the part of RTPE that runs
particles through a specified geometry and makes tallies of information that is of
particular interest to the user.
In rttMC, the true patient geometry is used rather than an approximation in order to
obtain the detailed edits necessary for BNCT. CT or MRI images taken of the patient are
loaded directly into RTPE, and a three-dimensional mesh is imposed over the top of these
images. This "subelement mesh" does not affect particle transport or tracking, being that
it is virtual and does not actually exist anywhere on the patient. As the particles are
tracked through this mesh, tallies are performed to determine total dose, boron dose,
gamma dose, nitrogen dose, fast neutron dose, neutron fluence for a specified number of
energy bins, and induced gamma production [19].
RTPE makes use of non-uniform rational b-splines, or NURBS. NURBS provide a
free-form curve and surface representation system, which incorporate the properties of b-
splines, interpolating splines, and Bezier curves and surfaces [19]. The NURBS replaced
a polygonal representation, in which simple geometric figures (such as cubes, cones, and
cylinders) are used to model certain bodies. NURBS can model more complex shapes
than polygonal geometry, and can more accurately depict the bodies on a CT or MRI
scan. The "non-uniform" aspect refers to a knot vector. This knot vector is actually a
series of nondecreasing scalar values that direct the curve about the control points [19].
In the RTPE environment, the user enters a number of control points to outline the
surface of the different regions of interest on the individual MRI or CT scans, such as
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skull, brain, and tumor. From these control points, the knot vector allows for continuity
in the curves. The b-spline uses a weighting scheme to determine the contribution each
control point makes to the position vector. At this point, RTPE then generates a file that
is a NURBS representation of a three-dimensional model based on the MRI or CT images
provided from the patient.
During the next few years of use, changes were made to the RTPE program to fix
problems that arose with the program during the clinical trials. Ultimately, an entirely
new program known as the Simulation Environment for Radiotherapy Applications
(SERA) was created. While both programs were created with the same basic structure,
SERA is different from RTPE in a few important ways. First, SERA is based on a pixel-
by-pixel uniform volume element (known as a "univel") reconstruction. Different bodies
are identified on the computer by filling in the pixels associated with each with a
different color. A name is given to each of these bodies, and information about each of
these bodies is available in the program: information such as elemental composition,
RBE factors of the various dose components, etc. The use of these univels gives SERA
the advantage of much shorter execution time for the transport calculations than RTPE.
Beam alignment in RTPE is done in the input file. The user specifies the beam
alignment by entering on the required line of the input file the beam's distance from a
point in the patient's head, the rotation about the azimuthal angle, as well as the rotation
about the polar angle. While the user-specified target point on the patient's head remains
fixed, the neutron source is rotated about this point. Both RTPE and SERA allow for
different types of output from the patient treatment plan. For instance, the user can
choose to output a dose-volume histogram (either for the whole brain, a particular
hemisphere, the tumor, etc.). Additionally, the user can output an isodose contour, which
will allow the user to determine if the chosen plan is administering too high a dose to a
particular region of the patient's brain.
The program used in the Harvard-MIT clinical trials is called NCTPlan. It was
initially designed around 1990, and was created to optimize the existing beam design
(dimensions, orientation, energy). The brain model used in this program is called
Neutron Photon Brain Equivalent (NPBE) model, and is created by two non-concentric
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ellipsoids. The elemental composition of this model has been documented by Zamenhof
et al. [20].
In 1996, after computational improvements were implemented, a new version of
NCTPlan was developed. This new version was written in Pascal, and called
MacNCTPlan because it was developed for a Macintosh platform. This MacNCTPlan
contains two major parts. Part I is where the three-dimensional mathematical model of
the patient's head is created from a set of MRI or CT scans using a "voxel" technique.
Part II is where the graphical environment exists, allowing the development of dose
patterns from the results of the particle transport calculations. It is here that the dose
distribution results can then be displayed in a one- two- or three-dimensional format.
Part I involves reconstructing the patient's head into a geometry form that the
computer can use. To do this requires the use of "voxels". Voxels are cubes of volume 1
cm3 (or possibly smaller), which are stacked in a three-dimensional array. A material is
assigned to each voxel, and the definitions of these materials can be found in a separate
material file. In MacNCTPlan, two sets of CT images are used: one with and one without
an iodinated contrast agent. The images with no contrast are used to determine what type
of tissue will make up the three-dimensional model for the MC calculations. The
contrast-enhanced images are used to identify the tumor and other bodies within the head.
This step is necessary to determine the region of interest (ROI), which contains the
tumor. From the chosen ROI, a diagram of pixel number versus Hounsfield number (H),
which is the measure of the X-ray absorbency, or density, of tissue, can be constructed.
This diagram will yield three peaks: one for the soft tissue (cancerous or normal), one for
the skull and one for the air. Each pixel is given a material assignment depending on its
corresponding H value. The final model contains 11,025 calculation cells, each
containing between 500-1000 voxels. A material is assigned to each cell by averaging
between four basic materials (air, tumor, normal soft tissue, and bone), with a weighing
factor depending on the number of voxels in a particular cell corresponding to each
material [20].
An important step in any treatment plan is setting up the beam alignment. In
MacNCTPlan, this means identifying the entrance and exit points of the beam's central
axis on the patient. Up to four different beams can be used for treatment. Two
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orthogonal viewing planes can be used through CT image data in MacNCTPlan. This
allows for real-time updating when changes are made to the beam orientation, and thus
the interaction of the beam with the patient's head model can be seen immediately. Also,
the locations of the beam entrance and exit points are necessary for patient positioning
during treatment. In MacNCTPlan, the neutron source is a plane source in a fixed
position with regards to the three-dimensional head model. When the user changes the
beam orientation, the software changes the location of the source plane, while the head
model remains the same. Once the model is created, a Fortran 77 program, called
MPREP, provides the MCNP input deck from a series of files. These files contain all the
information required for computing the doses within the model, including angular and
energy characteristics of the neutron and photon beams, material definitions, and values
for the kinetic energy released in matter (KERMA).
Part II of MacNCTPlan allows for viewing the dose patterns extracted from the
transport calculations that are performed by MCNP. These results (such as RBE isodose
contours) can then be displayed in one- two- or three-dimensional format. Dose-volume
histograms (DVHs) for the tumor, target volume, and whole brain can be generated as
well. This gives the user information on dose distribution, and the percent of particular
volumes subjected to a certain dose or dose rate. If multiple beams are to be used during
treatment, MacNCTPlan combines them in the treatment plan according to their weight,
which is generally defined as a function of the irradiation time.
A few years after MacNCTPlan was created, a new PC-based version of
MacNCTPlan, again named NCTPlan, was created in collaboration with the Comision
Nacional de Energia Atomica in Argentina (CNEA), Harvard Medical School, and MIT.
It was written in Microsoft Visual BasicTM 6.0 and runs under Windows 95/98/NT and
2000 [21]. This code was developed in order to update certain parts of MacNCTPlan, as
well as to create a software program that can be used on a more common computing
platform. MPREP was integrated into this program, and NCTPlan can superimpose
isodose contours on multiple orthogonal planes of the CT or MRI images. Another
difference between MacNCTPlan and NCTPlan is in the material assignment model.
Each image slice is constructed of a number of cells, and each of these cells is defined
based on its mixture of air, soft tissue, tumor, and bone. The percent composition of each
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of these materials is rounded off to the nearest percentage, but occasionally, the
procedure of rounding does not yield a total percentage of 100% in each cell. When this
happens, MacNCTPlan assigns to the cell the last admissible mixture calculated.
NCTPlan on the other hand searches for the mixture that minimizes the sum of the
relative differences (in absolute values). If this minimum value is not unique, the code
chooses the arrangement that has the least effect on the particle transport [21].
Additionally, changes in the calculation of DVHs were performed, which reduce the
errors due to the interpolation method.
As can be seen, RTPE and NCTPlan differ in a number of ways. Geometry
reconstruction, material definition, and kerma coefficients are among the significant
differences in the two programs. This thesis will not go into the effects of these
differences on the patient treatment plans, but they should be considered for a complete
pooling of patient data.
5. BNCT Intercomparison
Because of the small number of patients treated with BNCT, it is desirable to pool
patient data from different BNCT facilities. As is clear from the above discussion, it is
quite difficult to compare a patient treatment plan at one institution to one at a different
institution. Therefore, before a complete pooling of patient data can take place, each of
these differences must be evaluated. In particular, this thesis will focus on the differences
between the clinical trials at MIT and BNL. Among these differences are material
definitions (particularly elemental composition of 14N in normal brain tissue),
measurement of thermal neutron flux, fast neutron dose, and gamma dose at each
institution, and geometry definitions.
Over the years, there has been no single common source of elemental compositions of
tissue for all the institutions to use, and therefore different institutions use a different
value for the weight percent of 4N found in normal brain tissue. While BNL used a 14N
weight percent of 1.8 (the recommended value from an MIT workshop in 1989 [23]),
Petten and Harvard-MIT have most recently been using a value of 2.2% (MIT originally
used a value of 1.8%, however then switched in the past few years to use 2.2%), which is
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the value recommended by the ICRU report 46 (see Table 2) [22]. The 4N composition
is particularly important because of the thermal neutron interaction that takes place with
14N. Because of this difference in assumed 14N concentration, the two institutions are
actually stating that different 14N doses will be administered to a patient. If these doses
are significantly different, the effects may be seen in the total prescribed dose to the
patients.
Another difference is the definition and measurement of thermal neutron flux, as well
as fast and gamma dose measurement from one institution to another. Each institution
measures its beam dosimetry in the way that they feel is most accurate. However, this
means that most institutions are using different kinds of detectors, measuring in different
phantoms, measuring at different depths down the center line of the beam axis, etc. For
instance, at BNL, thermoluminescent dosimeters (TLDs) were used to measure the
photon dose rate, while at MIT, ion chambers were used. This has caused a systematic
difference in the doses reported by these different institutions for their respective beam
components. TLDs are small and produce a minimum perturbation of the neutron field,
but also are somewhat sensitive to thermal neutrons. This creates a high background that
must be subtracted. Each type of detector has its own advantages and disadvantages, as
well as each having its own associated error in a particular application. Because of this,
even in the same beam, the two types of detectors could give different readings. When
looking at a dose calculated from these measured values (such as thermal neutron dose
calculated from thermal neutron flux measurements), the error will propagate, which
causes concern when attempting to compare exposure from beams at different
institutions. The error associated with the neutron beam measurements must be evaluated
to determine the error associated with the prescribed dose. These measuring differences
make an intercomparison of patient doses from the two different trials even more
difficult.
Patient geometry at MIT and BNL is reconstructed using MRI or CT scans. When
phantoms such as the Lucite cube are run in RTPE, a simple combinatorial geometry
reconstruction is typically used. This is because phantoms such as the cube are more
easily modeled using a geometric reconstruction, and CT scans are unnecessary.
However, it is necessary to determine what effect the type of geometry (combinatorial vs.
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NURBS) has on the peak and whole brain average doses. Differences in patient
geometry within a single treatment planning system will be addressed later in this thesis.
As is quite obvious, the characteristics of the beams at different institutions are quite
different from one another. When a neutron beam is extracted from a reactor,
contaminating photons inevitably become part of the neutron beam. The extent to which
these contaminants are a part of the beam is different from one facility to another. Each
beam component must be thoroughly analyzed at each institution, and a direct means of
comparing each component from one institution to another must be determined. This
boils down to calculating a scaling factor for each dose component, allowing for a
comparison of prescribed peak dose between two institutions.
The use of different treatment planning software programs can also cause problems
when trying to compare patient data. For instance, NCTPlan and RTPE create the model
geometry in very different ways. So, while both model the same patient's head, neither
has created the head exactly, and the error associated with each modeling technique will
lead to slight differences in the ultimate treatment plans. Additionally, no two codes are
written exactly the same, and therefore differences in the particle transport and dose
calculations may arise.
Since ultimately, a full pooling of BNCT patient data is desired, all of the differences
between the participating facilities must be analyzed and evaluated. The effect of
different 14N concentrations, as well as scaling factors between the beam components
must be determined. Once these differences are understood, the MIT and BNL patient
data can be combined. The only normal brain side-effect observed in BNCT patients
suitable for use in a combined data set has been somnolence, and when the MIT and BNL
patients are combined, a more complete evaluation of the cause of this endpoint can be
examined.
The objective of these Phase-I clinical trials at BNL and H-MIT is to determine safety
and an estimate of normal tissue tolerance. The side effect observed in the central
nervous system (CNS) of some of these patients was a somnolence syndrome. The
objective of this thesis is to combine the clinical data from the BNL and MIT trials to
create a stronger set of data for evaluation of the BNCT dose-response relationship in
normal brain: in other words, an estimate of the tolerance of the normal brain to the
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complex radiation field produced in tissue during BCNT. Such information on brain
tolerance to BNCT will be of great importance in planning future clinical trials at MIT, as
well as at all other clinical BNCT sites worldwide.
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II. Materials and Methods
In comparing patient brain doses between clinical trials at two different clinical
centers, it is necessary to quantify any differences in dose measurements based on
systematic differences between different dosimetry techniques. Since the
intercomparison of the patient doses in this thesis is based upon the dosimetry
intercomparison reported by Riley et al. [1], a discussion of dosimetry techniques at BNL
and MIT is warranted. MIT and BNL used different phantoms to perform routine
dosimetry checks on their own beams, and also used different techniques to perform these
measurements. To directly compare the dosimetry techniques, measurements were
performed in the BNL beam by the MIT group in 1997 and 2000 using the standard BNL
phantom, as well as the standard MIT phantom [1] and the results were compared to the
published data from the BNL group [2]. The paper by Riley et al. [1] provides the basic
data required for the brain dose comparison in this thesis. Since all factors were the same
in both cases except for measurement techniques, a scaling factor between the MIT
measured doses and the RTPE output can be obtained for each dose component. These
scaling factors are a direct measure of the systematic differences in techniques. Again,
since this thesis mainly focuses on the differences between clinical trials at MIT and
BNL, only the dosimetry methods performed by each of these institutions will be
detailed. Both the BNL and MIT phantoms can be run in the RTPE treatment planning
system to benchmark the treatment plan against known measurements and to provide
preliminary insight as to differences between the two treatment planning systems.
1. Dosimetry Phantoms
Routine dosimetry measurements were performed by MIT in their own beam using
the MIT ellipsoidal water-filled phantom [3]. The ellipsoidal head phantom dimensions
are 13.6 cm in the x-direction, 19.6 cm in the y-direction, and 16.6 cm in the z-direction,
with a total volume of 2502 cm3 . The top two-thirds of the shell are made of acrylic, and
the bottom third is made of acrylic plates. The definition of these materials can be found
in Table 2. The shell is filled with distilled water, and watertight butyrate tubes are
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inserted from the bottom of the phantom. This allows gold foils or ionization chambers
that can be driven remotely by a computer-controlled stepper motor to be positioned
within the water medium. During the gold foil irradiations the tube containing the foils is
filled with water. When measurements are taken, the phantom is aligned with the beam
on the patient treatment table along the phantom's x-axis. It is positioned so that there is
no gap between the phantom and the plane of the end of the collimator. Figure 1 shows
the Deutsch and Murray model of the head. This was used as the basis for the MIT head
phantom. Figure 2 shows the dimensions and details of this phantom.
Table 2: Elemental composition for materials in the MIT ellipsoidal
Normalized Atomic Fractions
head phantom
Material H1 016 N14 Ca C Si
H20
Air
Acrylic
Quartz Mat. +
Acrylic Resin
1 ,6cm
- 13.6 cm 
12cm -*
Z axis.
Y axis
p _i
_
-r a ' l· .. '
Figure 1: A drawing of the Deutsch and Murray model of the head and brain using ellipsoids for the
inner and outer surfaces of the skull [3]
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Figure 2: Side and bottom view of the ellipsoidal water-filled head phantom showing how detectors
and activation foils can be inserted in hollow tubes into the internal water volume [3]
The phantom routinely used for dosimetry measurements at BNL was a solid Lucite
cube. The Lucite cube has dimensions 14 cm x 14 cm x 14 cm (total volume of
2744cm 3) and the composition is defined as 8% H, 60% C, and 32% N by weight. This
cube has a hole in the front face that extends down the centerline of the cube, as well as
off-axis holes, to accommodate various Lucite rods of 1.59 cm diameter. Slits are cut in
the rods at 3.5, 7.0, and 10.5 cm from the front face of the phantom, allowing for
measurements to be made at these depths by TLDs that can be placed in the slits. Rods
containing Au foils or Cd capsules with Au foils in them can also be placed in the Lucite
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cube for additional measurements. For thermal neutron flux measurements, these slits
can hold either a bare Au foil or a cadmium capsule in which an Au foil is placed. The
Au foils are square shaped and weighed between 3.02 + 0.03 and 25.59 + 0.26 mg [1].
Additionally, for gamma dose measurements or fast neutron dose measurements, an ion
chamber can be inserted instead of the Lucite rod, and can be located at a desired depth
by using spacers. To make measurements at additional depths, slits were created at 1.0,
2.0, 5.0, and 9.0 cm. For this study, the Lucite cube phantom was placed with its front
face touching the patient collimator, and its central axis aligned with the beam axis [1].
A diagram of the Lucite cube can be seen in Figure 3.
cm
I--
Figure 3: Diagram of 14cm x 14cm x 14cm BNL Lucite cube phantom
2. Dosimetry methods
For the BNL/MIT dosimetry intercomparison, measurements were performed by MIT
researchers in the BNL beam with the 12-cm collimator in place using both the MIT
ellipsoidal head phantom and the BNL Lucite cube. Data are available in the Lucite cube
from BNL using both the original 8-cm collimator, as well as the 12-cm collimator,
which was installed in 1996 [2]. Since the MIT measurements were performed only with
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the 12-cm collimator in place, a comparison of the BNL beam with the 8-cm collimator
cannot be performed at this time.
MIT researchers measured each beam component in December of 1997 and again in
July and September of 2000. Measurements were performed in the Lucite cube and the
ellipsoidal phantom for gamma dose, thermal neutron flux, and fast neutron dose. In-air
fast neutron dose measurements were also performed.
a. MIT gamma and fast neutron doses
Photon and fast neutron dose rates were measured in the Lucite cube phantom as well
as in-air using the dual chamber technique of Attix [4]. This technique involves using
two chambers: one that is neutron sensitive and one that is neutron insensitive. Using the
neutron insensitive chamber, the photon dose rate can be measured. The neutron-
sensitive chamber measures both gamma and fast neutron dose. Once these
measurements are known, the data from the neutron-insensitive chamber can be
subtracted from the data obtained from the neutron-sensitive chamber to determine the
neutron dose rate. The neutron sensitive chamber used by MIT is a 2.51 mm-thick A-
150-walled, muscle tissue-equivalent, ionization chamber (IC-18 Far West Technology)
that has an active volume of 0.1 mL and is flushed with tissue-equivalent gas (64.4%
CH4, 32.4% CO2, and 3.2% N2) at a rate of 20mlmin [1, 5]. The neutron-insensitive
chamber used by MIT is similar but has a 1.65 mm-thick wall made of graphite and is
flushed with CO 2 gas. Both chambers are operated with an applied voltage of +250 V
and have calibration certificates traceable to the National Institute of Standards and
Technology (NIST) [1, 5]. In-air measurements were also performed with the chambers
located along the central axis of the beam: the plane that defines the exit end of the
patient collimator. Overall uncertainties of about 9.0% are associated with the MIT
photon dose rate measurements [1, 5]. For the fast neutron dose rate measurements,
overall uncertainties in the Lucite cube are about 32.5% at a depth of 1 cm, and of 100%
at 4 cm and deeper, and uncertainties in-air are about 17% [1, 5]. In-phantom gamma
and fast neutron dose were made at 1 cm depth increments from 1 cm to 11 cm depth.
b. MIT thermal neutron flux
Thermal fluxes were determined using the cadmium difference technique. Au foils of
thickness 0.005 cm were used with 0.051 cm-thick Cd covers. Bare foils were irradiated
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at the surface of the phantom and at depths of 1 cm increments up to 8.0 cm, as well as at
10.0 cm and 12.0 cm. To minimize thermal flux suppression, the Cd-covered foils were
irradiated at the surface of the phantom and at depths with 2-cm increments up to 10.0
cm. MIT assumes that the thermal neutron activation occurs solely due to neutrons with
a velocity of 2200 m/s and have an absorption cross section of 98.8 barns [1].
Once the Au foils were activated, they were measured at MIT using a high-purity
germanium (HPGe) detector that had been energy-and-efficiency-calibrated using a
Standard Mixed Radionuclide Source (SRM 4275C-45) from NIST [1, 5]. This source
consists of a thin deposit about 0.6 cm in diameter on a polyester tape, and reproduces the
geometry of a Au foil. It is placed about 13 cm away from the face of the detector to
minimize coincidence-summing errors. Overall uncertainties of about 7.4% are
associated with the MIT thermal neutron flux measurements [1, 5].
c. BNL gamma and fast neutron dose rates
BNL researchers used the mixed-field ionization chamber dosimetry technique, based
on the methodology of Attix [4] for both gamma and fast neutron absorbed dose
measurements in air. This technique is the same as the one used by MIT, with one
neutron sensitive and one neutron insensitive ionization chamber. Both chambers are the
same as those used by MIT. Both chambers were calibrated at Far West Tech., Inc. by
'37Cs source irradiation [2]. They were covered with 6LiF thermal neutron shields made
by two 0.0794 cm-thick cellulose acetate butyrate cylindrical tubes, separated by -4 mm
thick 6LiF (-95% enriched isotopic 6Li) compressed powder and sealed at each end [2].
BNL measured gamma absorbed dose rates in the Lucite cube phantom by using LiF-
700 thermoluminescent dosimeters (TLDs) (Harshaw Chemical Company, Solon, Ohio
[2]). These TLDs are made of lithium fluoride, 99.93% enriched in 7Li, and are about
lmm x mm x 6mm. Unfortunately, they do contain small amounts of 6Li, which
responds strongly to thermal neutrons in the phantom. Because of this, each batch of
TLDs was calibrated for thermal neutron response at the Brookhaven Medical Research
Reactor's Thermal Neutron Irradiation Facility. The TLDs were calibrated for gamma
dose response in a calibrated 60Co source at BNL [2]. The TLD rods were covered with a
2 mm thick 6Li metal shield to measure the absorbed dose from gamma rays in the beam
at the irradiation aperture. The uncertainty in the measured photon dose rates is about
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10% [2]. The uncertainty in the fast neutron dose measurements in air is about 15% [2].
BNL researchers did not perform fast neutron measurements in the Lucite cube. Instead,
they relied on the in-air surface fast neutron measurement and calculations to generate
fast neutron depth-dose information.
d. BNL thermal neutron flux
BNL performed measurements to determine thermal and epithermal neutron fluence
rates, gamma dose rates, and fast neutron dose rates either in air or in the Lucite cube
phantom. Bare and cadmium-covered Au foils 0.00127 cm thick and with an average
diameter of 0.8 cm were used to measure thermal neutron fluence rates. However,
instead of using an HPGe detector to measure the activated foils as MIT did, BNL used a
NaI(T1) well-type detector to measure the Au foil activation. Calibration sources were
obtained from DuPont, and satisfied NIST standards [2, 6]. Uncertainty in the BNL-
measured thermal neutron fluence rates in both collimators is about 6% [2].
BNL assumes that thermal neutron activation occurs due to neutrons with a range of
energies. BNL calculates the energy distribution for thermal neutrons at each depth in
the phantom and determines an effective cross section associated with each position.
They calculated cross sections of 80.0, 83.0, and 86.0 barns at depths of 3.5, 7.0, and 10.5
cm, respectively [1]. This is different from the MIT definition of thermal neutrons, and
therefore when making a thermal neutron comparison, the fluxes cannot be directly
compared. However, when thermal neutron dose is calculated from the measured flux,
the difference caused by these different thermal neutron definitions disappears due to the
different kerma factors associated with the different cross sections.
e. Routine BNL dosimetry measurements in the Lucite cube
Beam measurements were performed by BNL on a monthly basis in the Lucite cube
at 3.5, 7.0, and 10.5 cm, between 1994 and 1999 as part of the BNCT clinical trial quality
control program. Figure 4 shows the photon dose and thermal neutron flux
measurements at 3.5 cm versus the date on which those measurements were taken. The
uncertainty in the experimental measurements over a one-year period of time in the 8 cm
collimator was about 5% [2]. The dosimetry methods used to obtain these measurements
are as described above. Between February 7, 1996 and March 27, 1996, a new collimator
was put in place at the BMRR. This new collimator was 12 cm in diameter and 7.6 cm
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thicker than the former 8-cm-diameter collimator. There is a clear decrease in thermal
neutron flux and gamma dose rate at this point. The thermal neutron flux decreases on
average by about 23% and the gamma dose rate decreases on average by about 34%.
This is due to the fact that while the 12-cm collimator has a larger neutron source area, it
is offset by the decrease in flux caused by the longer beam path (since the 12-cm
collimator is 7.6 cm longer than the 8-cm collimator). At the peak, the thermal neutron
flux decreases by 18% at 3MW power [2]. Additionally, some of the fuel rods were
shuffled between 2/10/98 and 3/12/98. The effect of this core shuffle can be observed in
both graphs by about a 15% increase in photon dose rate and 11% increase in thermal
neutron flux. When applying these changes to the RTPE source files, it was discovered
that the increase in flux and gamma dose rate after the core shuffle yielded an
insignificant change in the prescribed dose to the patient. Because of this, only three
treatment plans in the BNL clinical trial made use of a separate source definition after
2/10/98. All subsequent treatment plans used the source definition used before the core
shuffle. This means that two different source definition files were used to calculate the
treatment plans for these two groups of patients: those treated before and those treated
after the new collimator was put in place. Since MIT measurements were only performed
when the 12 cm collimator in place, all evaluation of adjustment factors will be
determined for this group. Without having the MIT measurements with the 8 cm
collimator, it is impossible to know whether or not two different sets of adjustment
factors should actually be applied to the patients. Thus, the adjustment factors calculated
below for the 12 cm collimator are used for all BNL patients.
All calculations in this thesis were performed specifically to compare the MIT clinical
trial to the BNL clinical trial. Access was available to all original patient treatment
planning information from both the BNL and MIT clinical trials, as well as to the original
computer used at BNL to run patient treatment plans using RTPE. It was important to
rerun patients treated at BNL on the BNL software because this would eliminate possible
errors associated with differences in treatment planning software. Particularly when
rerunning patient treatment plans, the original files (source, input, material, cross section,
etc) were used, and only one or two parameters were changed at a time, which allows for
the effect of these individual parameters on the treatment plans to be seen.
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With this information, a direct comparison of MIT measurements and BNL RTPE
output in the Lucite cube and the ellipsoidal head phantom can be performed. This will
allow for a calculation of the scaling factors that must be applied to all the BMRR dose
components so that they match MIT measurements. Ultimately, these scaling factors can
be applied to the BNL patient data, and a combined analysis of patient brain doses at MIT
and BNL can be achieved.
BNL Measurements Over Time
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Figure 4: Results of the routine gamma dose rate (bottom) and thermal neutron flux measurements
(top) performed by BNL from December 1994 to June 1999 [7]
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III. Differences in 14N Concentration
There is no standard reference that all centers must follow when defining tissue
composition, and therefore during the BNCT clinical trials, different centers used
different brain compositions, particularly '4N weight percent. The recommended values
changed over the years (as well as different values being recommended by different
groups), however the clinical centers treating patients with BNCT chose for themselves
whether or not to change the 14N values they used according to these recommended
values. For instance, while both MIT and BNL originally used a value of 1.8 weight
percent 14N for many years, MIT currently uses a value of 2.2 weight percent, as does
Petten. ICRU 46 defined normal brain as having 1.8% 14N [1]. These two percentages
are the two extremes of the 4N values used in BNCT. When attempting to pool the
patient data, the question arose as to what effect this difference in composition would
make in the ultimate definition of dose given to the patient, and what adjustment would
need to be made to patient treatment plans in order to compare patient data from an
institution using a nitrogen weight percent of 1.8% to one using 2.2%. By evaluating
these differences, a determination can be made as to whether or not a correction needs to
be made to BNL doses and RTPE output to match doses that would be as measured by
MIT in the same phantom.
The dose received by the patient during treatment is comprised of several different
components: a gamma component (from gamma rays in the neutron beam and a larger
component from the hydrogen capture reaction), a 14N dose component from the nitrogen
capture reactions in tissue (which creates a 615 keV proton), a fast neutron component
(from proton recoils produced by fast neutrons colliding with hydrogen in tissue), and a
boron-10 component (which is another thermal neutron dose and is proportional to the
amount of 10B in the tissue). The dose-depth distribution of each of these components in
a Lucite cube, containing no l°B, obtained from RTPE in the BNL beam can be seen in
Figure 5. The doses for this figure were calculated as the dose to normal brain tissue. All
doses stated in this thesis are calculated at a reactor power of 3MW.
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Physical Dose vs. Depth in Lucite Cube
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Figure 5: Depth-dose profile in Lucite cube (with no boron) for all components, using 12 cm
collimated source as calculated with RTPE
Table 3 shows the material definition of normal brain in RTPE with only the natural
concentration of boron in blood (which is almost zero). Table 4 shows the definition of
normal brain tissue as defined by ICRU 46 and MIT in 2002 [1, 2]. As can be seen from
Figure 5, the 14N dose is only a small contributor at all depths. It is in fact typically less
than 13% of the total dose at all depths. This is because 14N makes up such a small
fraction of normal brain tissue, and the fraction of the total dose that is from the 4N
reaction will depend on the weight percent 14N in tissue.
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Table 3: Material definition for normal brain in RTPE [3]
Material Atom Density Wt %
(atoms/barn-cm)
H 6.663E-02 10.57
0 2.886E-02 73.27
C 4.742E-03 9.03
N 8.283E-04 1.84
B 4.402E-09 0.00
Na 3.840E-05 0.15
Cl 5.340E-05 0.30
K 6.289E-05 0.39
P 7.939E-05 0.39
Table 4: Normal brain composition as defined by ICRU 46 [1] and by Harvard-MIT, as of 2002 [2]
Element ICRU 46 weight % Harvard-MIT weight %
H 10.7 10.57
C 14.5 13.94
N 2.2 1.84
O 71.2 72.59
Na 0.2 0
Mg 0 0
P 0.4 0.39
S 0.2 0
Cl 0.3 0.14
K 0.3 0.39
Ca 0 0
Density (g/cm3) 1.04 1.047
The first step in comparing the effect of 14N differences on patient doses at BNL or
Harvard-MIT is to make changes to a simple common phantom. In this case the 14cm x
14cm x 14cm Lucite cube containing no boron was chosen. While the particle transport
takes place through the material defined as Lucite (see Table 5), the dose is calculated in
normal brain tissue (see Table 3). The 14N weight percent in normal brain tissue can be
changed in the RTPE input file and the effect of this change on the calculated total dose
rate can be observed. By making the necessary material definition changes in RTPE and
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keeping all other input the same, the user is able to determine what effect changing the
nitrogen concentration has on the calculated dose to tissue.
Table 5: Material definition for Lucite as defined in RTPE
Material Atom Density
(atoms/barn-cm)
H 0.05777
O 0.01444
C 0.03511
With a nitrogen concentration of 1.8% (i.e., the BNL model), the nitrogen depth-dose
profile in the cube in the BNL beam is shown in the bottom curve in Figure 6. With a
nitrogen concentration of 2.2% (i.e., the MIT model), the nitrogen depth-dose profile in
the cube in the BNL beam is shown in the top curve in Figure 6. Figure 7 shows the
effect that varying the nitrogen concentration has on the total dose, which is the more
relevant parameter from a clinical point of view. This graph shows the total dose with no
boron present. As is clear from this graph, the difference between the two total doses is
very small. In fact, the two numbers are within 3% everywhere, including at the peak.
As mentioned before, the 14N dose comprises only a small percent of the total dose.
Because the other dose components (which can be seen in Figure 5) comprise a more
significant portion of the total dose, a small change in a component that makes up less
than 13% of the total dose will lead to an even smaller change in the total dose.
Additionally, this analysis included no boron in the normal tissue. Once the boron
component is added back in, the 14N component will comprise an even smaller percent of
the total dose, and the effect of changing this dose component will be even smaller.
Figure 8 shows a comparison of the 14N dose and the total dose in the Lucite cube for
tissue composition of both 1.8% and 2.2% 14N.
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N14 Dose Comparison in Lucite Cube
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Figure 7: Comparison of total dose rates in the Lucite cube
of either 1.8 % or 2.2 %
with no 10B, with nitrogen concentrations
43
2.0
1.8
1.6
- 1.4
E
. 1.2
a 1.0
4, 0.8
a 0.6
0.4
0.2
0.0
Figure 6:
or 2.2 %
12
10
8
6
4
S
.&
a
a)
(40
0
ae
2
0
Total and N14 Dose Comparisons for 1.8% and 2.2% N14 in Lucite Cube
IL
10
.' 8
8 4
2
0
- total dose (N14 = 2.2%)
--- total dose (N14 = 1.8%)
-A- N14 dose (2.2%)
X- N14 dose (1.8%)
0 2 4 6 8 10 12 14
Depth (cm)
Figure 8: Depth-dose profiles of both the 14N dose rates and the total dose rates in the Lucite cube
with no 10B, for nitrogen concentrations of either 1.8% or 2.2%
The results obtained from the Lucite cube indicate that the difference in peak dose
received by the patient due to differences in tissue nitrogen composition will be
negligible. However, to check this hypothesis, it is important to examine a sample
patient treatment plan, to be sure that the effect seen in the Lucite cube is representative
of that seen in a patient. Figure 9 shows the comparison of the 14N dose for a
representative 1-field patient treatment plan run with both 1.8% ' 4N in tissue and 2.2%
'
4N in tissue. The comparison of the total dose can be seen in Figure 10, along with the
14N dose. The peak dose for the 1-field patient is changed by less than 3%, and the total
dose actually changes by less than 3% everywhere along the curve. The 'normal brain'
for this patient was assumed to have a blood boron concentration of 10 ptg '°B/g. Almost
all patients treated in the BNL and MIT clinical trials had blood-boron concentrations of
between 10 and 20ptg/g.
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Figure 9: 14N dose rate comparison for a 1-field BNL
normal brain tissue using the 12-cm collimator
patient with either 1.8% or 2.2% nitrogen in
Dose Comparison for 1.8% and 2.2% N14 in 1-field Patient
-4-total dose (N14 = 1.8%)
- - total dose (N14 = 2.2%)
- N14 dose (1.8%)
- N14 dose (2.2%)
0 2 4 6 8 10 12 14 16 18 20 22
Depth (cm)
Figure 10: Total and 14N dose rate comparison for a 1-field
nitrogen in normal brain tissue using the 12-cm collimator
BNL patient with either 1.8% or 2.2%
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The dose administered to normal tissue is dependent upon the amount of '4N found in
the tissue. While different clinical centers use slightly different definition for the percent
composition of 14N in normal brain tissue, it is clear that the effect this difference has on
the total prescribed dose is negligible. Therefore, it is safe to say that a direct comparison
between BNL patient doses and MIT patient doses can be performed without the need of
any sort of scaling factor to account for the change in tissue nitrogen composition.
46
References:
1. ICRU 46: Photon, electron, proton and neutron interaction data for body tissues, 1992
2. M.R. Palmer, T. Goorley, W.S. Kiger m, P.M. Busse, K.J. Riley, O.K. Harling, R.G.
Zamenhof, Treatment planning and dosimetry for the Harvard-MIT Phase I clinical trial
of cranial neutron capture therapy, International J. Radiation Oncology Biol. Phys., 53:
1361-1379 (2002).
3. D.W. Nigg, F.J. Wheeler, D.E. Wessol, J. Capala, M. Chadha, Computational
dosimetry and treatment planning for boron neutron capture therapy, J. Neuro-Oncol. 33:
93-103 (1997).
47
IV. Comparison of Patient Dose Component Measurements in the
BNL Beam by BNL and MIT
In order to pool BNCT patient data from the various BNCT facilities, a direct
comparison of the dose administered to patients by two facility's neutron beams must be
made. To do this, an assessment of each facility's measurement techniques must be
performed. Every BNCT facility's neutron beam is unique in its dose component make-
up, and each component must be compared individually. For this evaluation, two
different phantoms will be used: the Lucite cube phantom routinely used by BNL, and the
ellipsoidal water-filled head phantom routinely used by MIT. These phantoms were both
simulated in RTPE using both a combinatorial geometry (CG), as well as geometry
reconstructed from CT images and compared to measurements in the actual phantoms. A
comparison of the CT to the CG geometry in each phantom showed that the same results
could be obtained regardless of geometry, and therefore all results will show the CG
geometry output. While the Lucite cube is the simplest geometry, it may actually be too
simple to rely upon for good results due to the fact that it does not closely resemble any
aspect of a potential patient to be treated with BNCT. Since the shape of the ellipsoidal
head phantom is more representative of an actual patient, it will therefore serve as a good
check of the accuracy of the model created from the Lucite cube.
1. Error Analysis of MIT & BNL Measurements
Before proceeding to examine the difference between the MIT and BNL dose
measurement techniques, it is necessary to examine the doses measured and published by
each group more closely [1, 2]. All of the BNL and MIT measurements have errors
associated with them (from measurement error, errors associated with the detectors, etc.).
These errors depend on number of counts in the detector and properties of the detector
itself, among others. It is important to fully understand these errors before doing further
evaluation.
Table 6 and Table 7 detail the measurements made by MIT and BNL in the BMRR
epithermal neutron beam with either the 8-cm collimator or the 12-cm collimator. These
measurements were all made in the Lucite cube phantom. The MIT measurements were
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performed in September 2000, and Ben Liu et al performed the BNL dose measurements
in 1996 [2]. The monthly quality control dosimetry measurements detailed previously
are in good agreement with the published BNL measurements [2, 3].
Table 6: MIT-measured dose rates, thermal neutron flux, and calculated 14N dose rates in Lucite
cube in the BMRR at a reactor power of 3MW with the 12-cm collimator (September 2000) [1]
Depth in Gamma Fast Dose Rate Thermal Flux '4N Thermal Dose
Cube Dose Rate (cGy/min) (cm-2s-l)*108 (calculated)
(cm) (cGy/min) (cGy/min)
1.0 4.84±0.44 2.38+0.70 -- --
2.0 5.62+0.51 2.00+ 1.00 -- --
3.5 5.76±0.52 1.25+1.00 13.73+1.02 1.10±0.08
5.0 4.93+0.44 0.36+035 -- --
7.0 3.75+0.34 0.38+0.37 4.88+0.36 0.39+0.03
10.0 1.60+0.14
10.5 1.29-0.12 1.13+0.08 0.09±0.01
Table 7: BNL-measured dose rates, thermal neutron flux, and calculated 14N dose rates in Lucite
cube in the BMRR at a reactor power of 3 MW with the 8-cm and 12-cm collimator [2]
Depth in 8-cm
Lucite collimator
Cube Gamma
(cm) Dose Rate
(cGy/min)
3.5 4.71±0.47
7.0 2.5+0.25
10.5 1.28±0.13
8-cm
collimator
Thermal Flux
(cm- 2 s-l)*108
19.4+1.2
6.41+0.38
1.53±0.09
8-cm 12-cm
collimator
'
4N Thermal collimator
Dose Gamma
(calculated) Dose Rate
(cGy/min)
(cGy/min)
1.56+0.10 3.87+0.39
0.516±0.031 2.45+0.25
0.123+0.007 1.27+0.13
12-cm
collimator
Thermal Flux
(cm-2s-l)*108
15.9±1.0
5.7±0.34
1.38±0.08
Measurements were also taken in the BNL beam by MIT in the ellipsoidal head
phantom. Unfortunately, equivalent measurements were not performed by BNL in the
same phantom. However, the MIT measurements in the head phantom will be useful as a
check on the accuracy of the scaling factor results obtained later in this thesis. The MIT
measurements in the ellipsoidal head phantom are detailed in Table 8.
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12-cm
collimator
'
4N Thermal
Dose
(calculated)
(cGy/min)
1.279+0.080
0.459+0.027
0.111±0.006
-
Table 8: MIT-measured dose rates, thermal neutron flux, and calculated 14N dose rates in the
ellipsoidal head phantom in the BMRR epithermal neutron beam at a reactor power of 3 MW with
the 12-cm collimator [1]
14N Thermal
Depth in Gamma Dose Thermal Neutron Dose
Lucite cube Rate Flux (calculated)
(cm) (cGy/min) (cm-2 s-l )*10 8 (cGy/min)
1.00 5.55+0.40 12.2±0.6 2.02+0.10
2.00 6.05+0.40 14.6±0.8 2.42±0.13
3.00 6.20±0.35 14.0±0.8 2.32+0.13
4.00 5.90±0.30 12.0+0.7 1.99±0.12
5.00 5.40±0.25 9.30±0.6 1.54+0.10
6.00 4.55±0.25 7.00+0.4 1.16±0.07
7.00 4.00+0.20 -- --
8.00 3.50±0.20 3.20+0.1 0.53±0.02
9.00 2.85+0.10 -- --
10.00 2.50±0.08 1.50±0.1 0.25±0.02
11.00 2.00+0.05 --
a. MIT measurement errors
The thermal flux was measured directly at a reactor power of 3MW in the solid
Lucite cube phantom by gold foil activation analysis [1]. With this flux value known, the
'
4N and 10B doses can be calculated by (assuming kerma coefficients for '4N and l°B of
0.745*108 and 8.66* 10-6 cGy-cm 2, respectively):
DN14 = (44.7 * 10-9)Fno in cGy/min (Eq. 1, [4])
DBIO = (5.196 * 10-4)Fb in cGy/min (Eq. 2, [4])
Where,
Fn = the fraction by weight of the nitrogen in tissue = 1.8%
Fb = the fraction by weight of the 10B in tissue = 10-20[xg/g
0 = the thermal neutron flux in neutrons/cm2s
Average 10B concentrations in the BNCT patients were typically between about 10
and 20tg/g, and therefore these values were used to calculate the minimum and
maximum °B dose rates to get an idea of the range of doses from U°B. The gamma dose
was measured by MIT directly in the cube in the manner described previously.
As can be seen from Table 6, the errors on the fast neutron measurements in the
Lucite cube are very large. Fast neutron doses in the cube were calculated using an A-
150 plastic walled ionization chamber, subtracting for the photon and thermal neutron
responses. Because the photon dose in the cube is higher than the photon dose in air, the
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error when measuring fast neutron dose in the Lucite cube is larger than measuring the
same way in air (greater subtraction is necessary in the cube, which allows for greater
error in the fast neutron measurement). Therefore, when calculating the total dose, it
would be more accurate to use the fast neutron measurement in air and scale the RTPE
fast neutron curve to this measurement, allowing for minimum error on the calculated
total dose. The MIT-measured fast neutron dose in air in July of 2000 was 1.71 + 0.29
cGy/min [1].
b. BNL measurement errors
In the same BNL beam, BNL researchers performed similar measurements. Bare
gold foils were used to measure the thermal neutron flux in the beam. These activated
gold foils were then measured with a NaI(T1) well-type detector [2]. It is important to
note that the thermal neutron flux measurements cannot be directly compared between
the two institutions. This is because the MIT group makes the assumption that thermal
neutron activation of the Au foils is due solely to neutrons with a velocity of 2200 m/s
(which have an absorption cross section of 98.8 barns [1]), while BNL calculates the
energy distribution for thermal neutrons at each depth in-phantom, and then determines
an associated average absorption cross section at each position. The values used by BNL
for thermal neutron absorption cross section are 80.0, 83.0, and 86.0 barns at 3.5, 7.0, and
10.5 cm, respectively [1]. Since calculation of the 14N and '0 B thermal neutron doses
take these kerma factors into consideration, the thermal neutron dose calculated from the
measured flux values at MIT and BNL must be compared instead. The gamma dose rates
in the cube were measured using LiF-700 TLD rods, the measurements from which can
be seen in Table 7. Since no measurements were made by MIT using the 8-cm
collimator, these numbers cannot be used for a comparison. Again, the most accurate fast
neutron dose will be obtained by scaling the RTPE output to the in-air fast neutron
measurements. The BNL-measured fast neutron dose in air with the 12-cm collimator
was 2.33 + 0.35 cGy/min [2].
Since no measurements were performed by BNL in the ellipsoidal head phantom,
only the Lucite cube will be used for the rest of this error analysis and dose comparison
between the two institutions.
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c. Physical dose comparison
From these data, the total physical dose in the Lucite cube can be calculated at
specific depths in the cube by:
Total Physical Dose = G + N + B + F [cGy/min] (Eq. 3)
Where,
G = gamma dose (cGy/min)
N = 14N dose (cGy/min)
B = l°B dose (cGy/min)
F = fast neutron dose (cGy/min)
And, assuming the uncertainties on these measurements are independent, the absolute
error on this calculated physical dose could be determined from the equation
+ + + (Eq. 4)
Where,
EG = error on the measured gamma dose
EN = error on the measured thermal neutron dose
eB = error on the measured boron dose
EF = error on the measured fast neutron dose
Using these equations, the values for total physical dose at 3.5, 7.0, and 10.5 cm and
their associated errors can be seen in Table 9.
Table 9: Calculated physical dose rates in the Lucite cube from published MIT and BNL
measurements. Errors represent the quadrature for summation. The calculations were performed
with either 10 or 10 jpg/g 10B
Depth MIT Physical Dose BNL Physical Dose MIT Physical Dose BNL Physical Dose
(cm) (l°B = 0lg/g) (l°B = 10 g/g) (l°B = 20 gg/g) ('°B = 20 g/g)
(cGy/min) (cGy/min) (cGy/min) (cGy/min)
3.5 14.57 ± 0.75 16.45 + 0.84 21.70 + 1.19 24.72 + 1.23
7.0 6.87 + 0.39 7.66 + 0.45 9.41 + 0.51 10.62 ± 0.55
10.5 2.68 0.18 2.83 + 0.18 3.27 + 0.19 2.55 + 0.19
d. Weighted Dose Comparison
The equation to calculate weighted dose is
Total Weighted Dose = RGG + RNN + RBB + RFF [cGy-Eq/min] (Eq. 5)
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Where all notation is the same as above and
RG = RBE factor for gamma dose = 1.0
RN = RBE factor for ' 4N thermal neutron dose = 3.2
RB = CBE factor for °1 B thermal neutron dose = 1.3
RF = RBE factor for fast neutron dose = 3.2
It is interesting to note that during the MIT clinical trials, a value of 0.5, instead of
1.0, was used for the RBE factor for gamma dose [5]. This was done because the dose in
the M-67 beam was delivered slowly and was fractionated (it was delivered over two
days). When calculating weighted doses, the question arises as to what error should be
associated with the RBE factors. These RBE and CBE factors have all been determined
experimentally [5], and unfortunately, the uncertainty on these numbers is unknown (and
possibly somewhat large). This problem will be addressed first by determining the error
on the weighted total dose assuming there is no error in the RBE factors, and secondly by
assuming the error on the RBE factors to be as large as 20%. While the errors on the
RBE factors have not been evaluated in great detail, it is known that they could possibly
be quite large. A value of 20% was assumed to be a reasonable, conservative estimate of
the RBE error. With no error on the RBE factors, the total dose error can be calculated
by
(Eq. 6)ew =/(R262 ) + (R2Fe2 ) + (RBeB2)+ (RFe ) . 6)
Where all notation is the same as that used previously. From this information, we get
values for the weighted total dose (Gy-Eq) and its associated errors at each depth in Table
10.
Table 10: Calculated weighted dose rates from MIT and BNL measurements in the Lucite cube with
either 0lpg/g or 20pg/g 10B, with no error on the RBE factors
Depth MIT Weighted Dose BNL Weighted Dose MIT Weighted Dose BNL Weighted Dose
(cm) (boron = 10 gg/g) (boron = 10 gg/g) (boron = 20 iag/g) (boron = 20 glg/g)
(cGy-Eq/min) (cGy-Eq/min) (cGy-Eq/min) (cGy-Eq/min)
3.5 20.38 + 0.95 22.77 + 1.00 29.66 + 1.53 33.51 + 1.54
7.0 8.92 + 0.44 9.91 + 0.49 12.22 ± 0.61 13.76 ± 0.63
10.5 4.63 ± 0.41 4.68 t 0.41 5.39 ± 0.42 5.79 ± 0.42
If a 20% error on the RBE factors is now assumed, the error equation becomes
53
e i2(R)((e d2 22))(N )(Rf )(() E .2 22))B )(R )((-) ( 0.2 ))+(F )(RF)((-) 0.2 )) (Eq.7)
The weighted total doses and their associated errors at each depth calculated from this
equation can be seen in Table 11.
Table 11: Calculated weighted dose rates from MIT and BNL measurements in the Lucite cube with
either 10lpg/g or 20pg/g 10B with 20% error on the RBE factors
Depth MIT Weighted Dose BNL Weighted Dose MIT Weighted Dose BNL Weighted Dose
(cm) (boron = 10 ,ug/g) (boron = 10 gg/g) (boron = 20 g/g) (boron = 20 gg/g)
(cGy-Eq/min) (cGy-Eq/min) (cGy-Eq/min) (cGy-Eq/min)
3.5 20.38 + 2.51 22.77 + 2.83 29.66 ± 4.25 33.51 4.82
7.0 8.92 + 1.13 9.91 + 1.26 12.22 + 1.66 13.76 ± 1.88
10.5 4.63 + 0.69 4.86 ± 0.70 5.39 ± 0.74 5.79 ± 0.77
2. Phantom Evaluation
To begin a comparison of the patient doses at BNL and MIT, the Lucite cube is used
to determine scaling factors between measurements made by the two institutions.
Measurements were taken at the BNL beam with the 12-cm collimator by MIT
researchers in June and September of 2000, and are summarized in Table 6 [1].
Measurements by BNL researchers were also taken in the same beam with both the 8-cm
collimator and the 12-cm collimator in place, and are summarized in Table 7 [2].
Systematic differences in measured values between BNL and MIT groups in the same
beam have been documented [1]. To compare and combine patient data from both MIT
and BNL clinical trials, it is necessary to analyze these dosimetry measurement
differences and apply a "correction factor" to one set. In this thesis, the BNL patient
dosimetry data will be adjusted to agree with MIT measurements.
Since the prescribed patient doses were generated from RTPE, and these are the
numbers that ultimately need to be evaluated, the RTPE output, not the BNL
measurements, should be compared against the MIT measurements for the sake of
consistency. Since the RTPE source definition models the BMRR epithermal neutron
beam very closely, the BNL measurements and the RTPE output should match up very
well. This can be checked for gamma dose and thermal neutron flux. Figure 11 and
Figure 12 show the thermal neutron flux and gamma dose rate measurements,
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respectively, compared to the RTPE output. These graphs show that the BNL
measurements do in fact match up well with the RTPE output, particularly the thermal
neutron flux, which has the greatest effect on the total dose. Therefore, it is valid to
compare the RTPE output to the MIT measurements.
Thermal Flux Comparison
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* rtpe output
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16.00
Figure 11: BNL thermal neutron flux measurements [2] compared to RTPE output in the Lucite
cube with the 12-cm collimator
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Figure 12: BNL gamma dose rate measurements [2] compared to the RTPE gamma dose rate output
in the Lucite cube for the 12-cm collimator
Since the approach taken for this combination of patient data is to adjust the BNL
patient doses to match the MIT measurements of the BMRR epithermal neutron beam, it
is necessary to examine each dose component individually and to compare the depth-dose
curves in the Lucite cube for both the MIT measurements with the RTPE output. Once
scaling factors have been determined in the Lucite cube, they can be applied to the
ellipsoidal head phantom. Using this additional phantom will provide a check on the
scaling factors calculated from the Lucite cube. It is expected that with the use of the
scaling factors, the output from the ellipsoidal head phantom will match up well with the
measurements performed in the BMRR epithermal neutron beam by MIT in the same
phantom.
3. Thermal Neutron Dose
As mentioned above, the thermal neutron flux was measured by MIT, and thus the
thermal neutron doses due to 14N and l°B can be calculated using Equations 1 and 2.
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Different cross sections were used for thermal neutrons by MIT and BNL, so the fluxes
cannot be directly compared. Because of this, it is important that the thermal doses (14N
and 10B) instead be calculated and compared. In determining the scaling factors, the
simple ratio of MIT dose divided by the BNL dose at the same depth is calculated. When
this is done, a scaling factor can be calculated that scales the RTPE thermal neutron dose
output to match the MIT measurements using a least squares fit. The fractional error on
the scaling factor is equal to the fractional error for each of the MIT measurements. The
scaling factor calculated in the Lucite cube for this dose component is 0.90+0.07.
Because both the 14N and l°B dose components are calculated from the thermal neutron
flux, both should have a similar scaling factor between the BNL doses and the MIT
measurements. When calculated, the scaling factor for the l°B component in the Lucite
cube was 0.93_0.07. As it is clearly seen, the two are in fact very close, and the error
bars overlap. Therefore, one scaling factor for both thermal neutron dose components
will be calculated by averaging the two individual scaling factors, and a thermal neutron
scaling factor of 0.92+0.07 will be used. Figure 13 and Figure 14 show the 14N dose and
the l°B dose in the Lucite cube with and without this adjustment factor of 0.92.
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N14 Dose Comparison (Lucite Cube)
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Figure 13: 14N dose rate scaling in Lucite cube with scaling factor 0.92 compared to original RTPE
14N dose rate output and 14N dose rates calculated from MIT measurements
B10 Dose Comparison (Lucite Cube)
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Figure 14: J°B dose scaling in Lucite cube with 15ppm 0°B with scaling factor 0.92 compared to
original RTPE °B dose rate output and 10B dose rates calculated from MIT measurements
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4. Gamma Dose
The same sort of comparison is performed on the gamma dose rates. When the least
squares fitting is applied to the Lucite cube RTPE gamma dose rate output, a scaling
factor of 0.74±0.06 is calculated by dividing the MIT measurement by the BNL
measurement at each depth that a measurement was performed. The output from RTPE
with and without this scaling factor can be seen in Figure 15.
Gamma Comparison (Lucite Cube)
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Figure 15: Photon dose rate in the Lucite cube with a scaling factor of 0.74 compared to original
unscaled RTPE photon dose rate output and MIT photon dose rate measurements
5. Fast Neutron Dose
As mentioned previously, the error on the fast neutron measurements in the phantoms
is quite large due to the greater subtraction for photons in-phantom. Since the error on
the in-air measurements is much smaller, these measurements will be used to obtain the
fast neutron scaling factor. The MIT in-air fast neutron measurement was 1.71±0.29
cGy/min [1], and the BNL in-air fast neutron measurement was 2.33±0.35 cGy/min [1].
The scaling factor obtained from these measurements is 0.73+0.12. To obtain this scaling
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factor, the MIT in-air measurement was divided by the BNL in-air measurement, and the
fractional error on the scaling factor is the same as the greater fractional error on the two
measurements (17%). Figure 16 shows the Lucite phantom fast neutron dose output,
both scaled and unscaled, compared to the in-air fast neutron measurements by MIT and
BNL.
Fast Neutron Adjustment
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Figure 16: In-air fast neutron measurements by both BNL and MIT compared to fast neutron RTPE
output in Lucite cube phantom with a scaling factor of 0.73 and original, unscaled RTPE output
6. Ellipsoidal Head Phantom
To check these scaling factors, the ellipsoidal head phantom can be used. Since
measurements were performed in the BMRR epithermal neutron beam by MIT in this
phantom, running the head phantom through RTPE with the scaling factors applied
should yield dose curves that match with the MIT measurements. The curves for each of
the dose components can be seen in Figure 17, Figure 18, Figure 19, and Figure 20.
These graphs show that the results from the head phantom do, in fact, match up fairly
well with the MIT measurements, especially when the error on the scaled RTPE curve is
taken into consideration. The error on the scaled RTPE curve arises mainly from the
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error on the scaling factors, but partially from the error inherent with RTPE. This error
comes to between about 5% and 10%, and will cause the scaled RTPE curve to overlap
with the MIT measurements.
N14 Dose Comparison - EIIHP
* rtpe
O mit meas.
A rtpe-scaled (0.92)
0 1 2 3 4
Depth (cm)
5 6 7
Figure 17: Unscaled RTPE '4N doses in the ellipsoidal head phantom, 14N doses calculated from MIT
measurements, and the scaled RTPE output using a scaling factor of 0.92
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Figure 18: Unscaled RTPE 1°B doses in the ellipsoidal head phantom, L°B doses calculated from MIT
measurements, and the scaled RTPE output using a scaling factor of 0.92
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Figure 19: Unscaled RTPE gamma doses in the ellipsoidal head phantom,
MIT, and the scaled RTPE output using a scaling factor of 0.74
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Figure 20: Unscaled RTPE fast neutron doses in the ellipsoidal head phantom, in air fast neutron
doses measured by MIT and BNL, and the scaled RTPE output using a scaling factor of 0.73
7. Total Physical Dose
The final adjustment factors are summarized in Table 12.
Table 12: Adjustment factors necessary to scale RTPE output to match MIT measurements
4N 'B Gamma Fast Neutron
Scaling Factor: 0.92 0.92 0.74 0.73
Now that the individual adjustment factors have been determined, it is necessary to
see how these factors must be combined to ultimately adjust the BNL patient brain doses
(both peak and whole brain average). By applying all the factors together, we determine:
D = 0.74DG + 0.92DN + 0.92DB+ 0.73DF in cGy/min (Eq. 8)
Where DG is the gamma component of the total dose, DN is the ' 4N thermal neutron
component of the total dose, DB is the boron component of the total dose, and DF is the
fast neutron component of the total dose. The top curve in Figure 21 shows the original
RTPE output in the Lucite cube, along with this new lower adjusted total dose in the
Lucite cube and the MIT total physical dose calculated from the MIT measurements.
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Figure 21: Total physical dose rate output from RTPE with and without adjustment factors in Lucite
cube with 15ppm 10B compared to total physical dose calculated from MIT measurements
The difference between the two physical dose rate curves ranges from 15% to 25%
depending on depth in the cube. At the peak, the adjusted curve is 15% lower than the
original curve for the Lucite cube. On average the adjusted curve is about 18% lower
than the original curve in the cube.
Further analysis of this curve (i.e., finding a more accurate, single adjustment factor
for the total dose curve) will not be done because this adjustment factor would only apply
to two-dimensional analyses. Since we are more interested in the effect on patient dose-
volume histograms and peak and whole brain average doses, further work with the
phantoms is unnecessary.
8. Weighted Doses
Prescribed patient doses are quoted in terms of weighted doses (Gy-Eq), so it is
important to observe the effect of the adjustment factors on weighted doses in the
phantoms. The weighted doses can be obtained by applying the RBE factors mentioned
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previously. When the adjustment factors are applied to the Lucite cube and compared to
the weighted doses calculated from the MIT measurements, Figure 22 is obtained. These
calculated MIT doses assumes no error in the RBE factors. Figure 23 shows the total
weighted dose calculated assuming a 20% error on the RBE factors.
Weighted Dose Comparison in Lucite Cube
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Figure 22: Adjusted and unadjusted total weighted dose in Lucite cube with 15ppm 0°B from RTPE
compared to total weighted dose calculated from MIT measurements
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Figure 23: Adjusted and unadjusted total weighted dose rates in the Lucite cube with 15ppm l°B
from RTPE compared to total weighted dose calculated from MIT measurements assuming 20%
error on RBE factors
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V. Application of Scaling Factors
1. Applying Adjustment to Patient Data
Now that the comparison of the beam components is complete, the values determined
to be the necessary adjustment factors can be applied to the BNL patient data. All the
patients have a different I°B concentration, and the adjustment must be applied to a three-
dimensional output, and therefore a single adjustment factor cannot be applied to the
existing defined peak and whole-brain average doses. To apply the adjustment, the
patient treatment plans were rerun in RTPE, with the adjustment factors included in the
input file. The actual particles need not be rerun; only the dose calculation edits need to
be rerun. Therefore, changes were made to the definitions of the RBE factors in the edit
directives section of the input file. By multiplying the existing RBE factors by the new
scaling factors corresponding to the same dose component, both the RBE factors and the
adjustment factors can be applied to this dose component. Table 13 shows the new peak
and average brain doses obtained when all of the BNL patients are rerun in RTPE. As
can be seen, the new peak dose numbers are about 16% lower than the original numbers.
The new whole-brain average doses are about 18% lower than the original RTPE output.
It is of particular interest to observe the effect the adjustment factors have on the dose
distribution in normal brain tissue. This can be viewed by looking at the integral dose-
volume histogram (DVH) information RTPE outputs. Figure 24, Figure 25, and Figure
26 show representative DVHs for 1, 2, and 3-field patient treatment plans, respectively.
The solid line in each figure represents the original DVH, and the dotted line represents
the DVH of the treatment plans rerun with the adjustment factors. These plots show that
the general shape of the curve remains the same, but the curves are simply shifted.
Therefore, the fractional dose distribution in the normal brain tissue does not change
significantly when the BNL dose is adjusted to match the MIT dose, even though the
peak dose changes by about 16%. Table 13 shows all BNL patients from protocols 1-8
with and without the adjustment factors applied to their peak and whole-brain average
dose values.
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Figure 24: Dose volume histogram for 1-field BNL treatment plan with and without adjustment
factors
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Figure 25: Dose volume histogram for 2-field BNL treatment plan with and without adjustment
factors
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Sample DVH for 3-field BNL Patient
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Figure 26: Dose volume histogram for 3-field BNL treatment plan with and without adjustment
factors
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Table 13: BNL data on patients treated with BNCT - date of treatment, number of fields each
patient was treated with, and unadjusted and adjusted peak and whole brain average weighted doses
# of Original Peak Adjusted Peak Original Average Adjusted Average
Pt # Date fields (Gy-Eq) (Gy-Eq) (Gy-Eq) (Gy-Eq)
1 9/13/94
2 2/2/95
3 4/13/95
4 4/27/95
5 6/15/95
6 6/22/95
7 6/29/95
8 6/30/95
9 7/13/95
10 7/20/95
11 10/5/95
12 10/13/95
13 11/30/95
14 2/1/96
15 2/22/96
16 6/6/96
17 6/13/96
18 7/11/96
19 7/25/96
20 8/1/96
21 9/12/96
22 9/19/96
23 10/17/96
24 11/7/96
25 11/14/96
26 12/11/96
27 12/18/96
28 1/9/97
29 1/23/97
30 1/30/97
31 5/29/97
32 6/11/97
33 6/18/97
34 8/13/97
35 10/8/97
36 11/12/97
37 12/31/97
38 2/4/98
39 6/3/98
40 6/24/98
41 8/19/98
42 10/21/98
43 11/25/98
44 12/2/98
1 10.08
1 8.88
1 10.52
1 10.53
1 10.86
1 10.51
1 10.28
1 13.26
1 10.97
1 10.67
1 10.80
1 11.63
1 10.62
1 12.65
1 13.14
2 11.94
1 12.60
2 12.95
2 12.86
2 13.75
1 14.22
1 13.16
1 14.39
1 12.45
1 12.27
1 12.61
2 11.90
2 12.19
2 11.94
1 12.48
1 13.80
1 13.05
2 12.60
2 12.45
2 12.78
1 14.83
2 13.34
2 12.57
2 12.73
2 12.21
2 12.40
3 14.59
3 14.91
3 15.63
8.40
7.45
8.79
8.79
9.06
8.83
8.58
11.01
9.22
9.01
9.07
9.65
8.88
10.52
10.95
10.06
10.70
10.72
10.63
11.42
11.85
11.01
12.08
11.03
10.22
10.57
9.83
10.07
10.07
10.73
11.56
10.90
10.58
10.45
10.77
12.66
11.22
10.59
10.67
10.16
10.50
12.03
12.55
13.26
2.31
2.04
2.13
2.23
1.93
2.24
2.27
2.66
2.85
2.09
2.27
2.23
2.64
2.44
2.40
4.55
3.35
4.93
4.50
5.72
4.16
3.72
3.74
3.41
3.26
3.76
5.24
4.08
4.84
3.70
3.59
3.73
5.30
5.00
5.27
3.79
5.95
4.69
5.46
6.57
5.31
9.38
7.99
8.36
1.87
1.67
1.74
1.81
1.57
1.84
1.85
2.16
2.34
1.72
1.86
1.80
2.15
1.98
1.94
4.14
2.87
4.00
3.72
4.67
3.38
3.02
3.13
2.80
2.65
3.08
4.22
3.38
3.93
3.12
2.93
3.03
4.35
4.12
4.39
3.23
4.89
3.86
4.46
5.35
4.49
7.60
6.60
6.97
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45 12/9/98 2 12.92 10.94 5.22 4.32
46 12/10/98 3 14.65 12.38 8.09 6.70
47 12/16/98 3 15.43 12.88 8.13 6.65
48 12/17/98 2 11.29 9.54 4.78 3.95
49 1/13/99 3 15.64 13.05 9.07 7.41
50 3/10/99 3 14.13 11.99 8.70 7.21
51 3/26/99 3 14.77 12.40 6.71 5.50
52 4/28/99 3 9.5 7.97 4.4 3.60
53 5/7/99 3 12.6 10.58 7.6 6.24
54 5/20/99 3 14.0 11.77 7.5 6.15
2. Applying Adjustment to Tumor Data
Another important application of these scaling factors is to tumor doses. It is
important to know what dose the tumors are getting because it is these cells that the
treatment is targeting. If the tumor cells do not get sufficient dose, they will not die, and
the tumor will recur following treatment. Unfortunately, since the limiting factor in how
much dose can be administered during BNCT is normal tissue tolerance, the tumors
frequently do not get enough dose and do in fact recur. However, it will be interesting to
pool tumor doses along with the whole brain doses. Table 14 shows the doses applied to
BNL patients' tumors before and after the scaling factors have been applied. It is
important to note that researchers are more uncertain of the 1°B CBE factor in tumor.
The CBE factor used for BPA is 3.8 [2]. Ideally, CBE factors for BPA and BSH should
be derived using survival data, but this has been difficult with the intracranial 9L
gliosarcoma due to the normal tissue complications resulting from the large single
fractions of X rays needed to control this tumor [2]. Additionally, it is not known
whether or not all tumor cells accumulate boron. Figure 27 shows a sample tumor DVH
for a 1-field patient with and without the adjustment factors.
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Table 14: Adjusted and unadjusted peak and average weighted doses to tumor for each patient
treated with BNCT at BNL
Original Adjusted Original Adjusted
Pt # Peak Peak Average Average
(Gy-Eq) (Gy-Eq) (Gy-Eq) (Gy-Eq)
1 47.60
2 53.79
3 49.46
4 48.69
5 50.53
6 47.52
7 48.60
8 64.36
9 54.50
10 55.57
11 51.52
12 53.82
13 50.73
14 56.37
15 60.67
16 60.00
17 63.00
18 56.00
19 54.00
20 58.00
21 62.00
22 61.00
23 69.00
24 68.00
25 55.00
26 60.00
27 49.00
41.39
40.02
45.09
43.91
46.00
48.22
43.41
53.92
49.66
50.77
48.64
46.53
44.87
51.18
55.15
63.78
57.88
50.46
49.20
56.22
57.94
52.22
62.78
62.15
50.21
54.60
44.66
42.37
45.45
41.89
37.67
37.55
40.48
37.30
48.10
43.45
46.23
48.29
37.33
44.08
42.43
38.52
49.36
53.00
37.00
45.00
47.00
48.00
48.00
59.00
58.00
51.00
47.00
36.00
38.35
40.61
38.35
33.67
33.83
41.95
33.32
42.27
40.23
42.02
45.06
33.24
40.92
38.35
35.00
51.98
48.16
30.75
39.53
45.65
44.18
43.50
53.42
53.09
46.11
42.77
32.13
Original Adjusted Original Adjusted
Pt # Peak Peak Average Average
(Gy-Eq) (Gy-Eq) (Gy-Eq) (Gy-Eq)
28 56.00
29 66.00
30 58.00
31 66.00
32 59.00
33 68.00
34 65.00
35 65.00
36 83.70
38 63.83
39 59.23
41 66.11
45 69.37
48 59.09
37 65.99
40 53.00
42 60.19
43 76.84
44 86.31
46 78.57
47 72.28
49 73.20
50 77.93
51 77.72
52 54.14
53 48.22
54 75.33
50.74
52.86
53.48
59.91
54.06
61.88
59.97
59.03
76.69
58.40
53.86
60.45
63.45
53.99
58.62
48.13
54.45
70.14
78.54
71.83
65.77
66.59
71.33
70.73
49.27
43.88
68.55
52.00
55.00
50.00
57.00
55.00
65.00
55.00
52.00
74.90
63.31
46.35
56.69
39.04
55.14
54.61
47.00
54.11
64.40
79.19
69.73
53.80
64.96
63.16
63.08
43.97
31.74
54.19
47.26
50.25
45.73
51.64
50.38
59.15
50.21
47.65
68.65
57.83
42.05
51.91
35.54
50.27
49.98
42.52
48.80
58.66
72.40
63.72
48.81
58.94
57.68
57.40
40.01
28.88
49.31
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Figure 27: Dose volume histogram to tumor for sample 1-field BNL treatment plan with and without
adjustment factors
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VI. Somnolence Endpoint
With traditional photon therapy administered to tumors in the brain, there are a
number of side effects the radiation can cause. These side effects are divided into two
categories: acute and delayed. Acute effects occur immediately following radiation
treatment (a few days to a few weeks), and are generally temporary or can be managed
with medical interventions. Acute effects in the CNS are not necessarily due to damage
to the normal brain. One acute effect reported in both the BNL and the MIT BNCT
clinical trials is an increase in intracranial pressure due to the response of residual tumor
volumes that were larger than 60 cc [1, 2]. Delayed effects occur much later, and can be
classified as either early or late. Early delayed effects typically occur between one and
six months following treatment. Late delayed effects occur six months or more after
therapy and are usually irreversible. One delayed side effect is necrosis, which is death
of normal cells or tissue. Necrosis in normal brain tissue can lead to undesirable effects
on the patient's motor skills, speech, etc, depending on the location and the volume of the
area involved. Necrosis is characterized as a late delayed effect, is irreversible, and can
be lethal [3]. Another delayed side effect is somnolence syndrome, which is
characterized by periods of drowsiness, lethargy, loss of appetite, and irritability
following radiation treatment. Somnolence is an early delayed effect. The somnolence
syndrome was first observed in children treated with brain irradiation as part of a whole-
body irradiation-conditioning regimen prior to bone marrow transplant, but it is also
frequently observed in adults treated for brain tumors [4]. Both necrosis and somnolence
have also been observed in BNCT. Necrosis has been reported in some of the long-term
survivors of the Japanese BNCT protocols [5].
It has been of great interest to determine the cause of these radiation side effects. The
mechanism of radiation induced side effects in the brain and other tissues is still a matter
of considerable debate: the question is whether the target cell population is the vascular
endothelial cells or the functional brain cells [6]. The cause has been thought to be a
primary cell population, the inactivation of which, following irradiation, results in these
side effects [3]. Additionally, it has been observed that the lesions in the central nervous
system (CNS) following irradiation are similar to the lesions created following other
types of CNS damage, and therefore the reaction of the CNS to irradiation may have
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similar mechanisms to other forms of damage. Direct damage to the CNS results in acute
cell death, secondary reactive processes, and enhanced cytokine gene expression [3].
These responses have all been observed following radiation injury as well.
During BNCT, as with other types of radiation therapy, the cause of the side effects is
simply the administration of too high a dose, either to the whole brain or to a specific
region of the brain. During the BNCT clinical trials, one of the objectives was to
determine what this brain tolerance was. There are three phases of clinical trials. A
phase I clinical trial is a safety and dose-escalation study. The dose administered to small
groups of patients is slowly increased over time until an unsatisfactory endpoint is
reached. A phase II clinical trial is performed after the phase I trial is completed, and is
performed to further determine side effects and how to manage them, as well as to
determine the most effective dose to use during treatment. In a phase III trial, the new
treatment is compared against currently existing treatments and to determine how
effective these new treatments are. Phase mII trials use large enough numbers of patients
for statistical significance.
During the BNCT clinical trials, the question arose as to what endpoint should be
used to determine the maximum brain dose acceptable to administer to the patient.
Death, or length of survival post-BNCT, is an unacceptable endpoint due to a couple of
factors. One is that before a radiation dose high enough to cause death is administered,
effects on the patient's mental status will be seen. Secondly, the unfortunate fact is that
even with BNCT, all the patients will die, usually within a year, and it is almost
impossible to know how much the BNCT contributed to that death. In other words,
patients with GBM generally do not live long enough to develop the classic late effects in
the brain. Additionally, a patient may receive another form of therapy following BNCT,
and it is impossible to know to what extent BNCT contributed to the patient's quality of
life following all of his or her treatments. The only other side effect that has been seen as
a reasonable endpoint is somnolence.
In traditional radiotherapy, somnolence has been found to occur in a somewhat
cyclical pattern. It has been found that somnolence occurs in patients typically between
about day 11 and day 21 and from about day 31 to day 35 following radiotherapy. While
the severity of the symptoms was shown to increase due to accelerated fractionation, the
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cyclical pattern of the symptoms did not change [2]. It has been determined that necrosis
is related to location of the irradiation and the total volume of brain tissue that receives
greater than 12 Gy of photons [7]. Flickinger et. al. [8] showed that the volume of tissue
receiving 12 Gy or more (termed the "12-Gy-Volume") accurately reflected the risk of
postradiosurgery MRI images showing changes indicating radiation damage. It is well
recognized that the occurrence of side effects are directly related to the volume of brain
tissue irradiated. This most likely holds for BNCT as well as for conventional
radiotherapy. In BNCT, the dose is administered as a whole-brain dose. Because of this,
the occurrence of somnolence could be a combination of multiple locations receiving a
dose sufficient to cause somnolence.
1. Peak and whole brain average dose relationship
54 patients were treated with BNCT at BNL during the duration of their clinical trial.
Of these 54 patients, 11 showed symptoms of somnolence. These 11 included 9 patients
treated with 3 fields (7 from protocol 5 and 2 from protocol 6), and two patients treated
with 2 fields (protocol 4b). When all the patients' whole-brain average doses are plotted
against their peak brain doses, Figure 28 is generated. This figure shows that the risk of
somnolence greatly increases above a whole-brain average dose of about 6 Gy-Eq.
Figure 29 shows the actual dose response curve for this data. From this curve, it can be
observed that at 6.1 Gy-Eq, the risk of producing somnolence is about 50%.
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Figure 28: Original prescribed peak vs. whole-brain average weighted doses for all BNL patients
with data on which patients showed somnolence following treatment
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Figure 29: Dose response curve for somnolence for all BNL patients treated with BNCT
To get a more accurate representation of the cause of somnolence syndrome, the
patients treated with the MIT M67 beam should be included in this study. With the BNL
scaling factors determined previously based on the dosimetry intercomparison [9], this
patient pooling can now be done. To do this, the BNL patient doses from Table 13 must
now be used. When the BNL and M67 patient data are combined, Figure 30 is obtained.
This figure shows MIT and BNL patients who did and did not exhibit somnolence, along
with two MIT metastatic melanoma patients treated with BNCT, neither of which
exhibited somnolence. This figure singles out the BNL patients in protocols 6, 7, and 8
because these patients were either treated with fractionated BNCT (protocols 6 and 7), or
were treated for recurrent GBM (protocol 8), and therefore their treatment was different
from the other BNL patients (protocols 1-5) and should be noted. From this figure, it is
clear that there is no longer a clear-cut dose, either on the whole brain average axis or the
peak dose axis, above which all patients exhibit somnolence and below which none
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exhibit somnolence. It does appear, however, that patients receiving a whole-brain
average dose of greater than about 5 Gy-Eq have a higher chance of exhibiting
somnolence syndrome than those below this dose. By including patients from more
clinical trials, a better idea of exactly what the relationship is between whole brain
average dose and somnolence syndrome can be determined. Looking at a dose response
curve, Figure 31 gives a better idea of the risk of causing somnolence associated with the
various doses.
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Figure 30: BNL and MIT patient peak vs. whole-brain average doses (adjustment factors applied to
BNL patient doses) along with data on which patient showed symptoms of somnolence following
treatment [1]
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2. Patient Details
It is important to make sure that the patients included in the study do not have any
abnormalities in their treatment or follow-up, and that there are no other factors that
might influence whether or not the patient shows symptoms of somnolence. One major
factor that must be taken into account in the pooling of patients is that different
physicians are in charge of different patients. Because of this, and because somnolence is
not a clear-cut endpoint, the physicians may not be scoring the somnolence in the same
manner (i.e., while one physician might claim a patient is showing symptoms of
somnolence, another might disagree). In calculating the dose response curve, it was
decided that one of the MIT patients should excluded. This was the metastatic melanoma
patient seen in Figure 30 to have a whole brain average dose of about 7 Gy-Eq. This
patient was excluded from the dose responses curve because he or she received
chemotherapy following the BNCT, and slipped into a coma before a full evaluation of
whether or not he or she exhibited somnolence could be performed. Therefore, it is
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difficult to say whether or not he or she showed symptoms of somnolence, and in fact
after a discussion with the doctor monitoring the patient, it was decided that this patient
might in fact have been exhibiting symptoms of somnolence, though it was never
recorded. It is also important to remember that the BNL patients in protocols 6, 7, and 8
were either treated with fractionated BNCT or for recurrent GBM. Because this has no
effect on the whole brain average dose received during the BNCT treatment, these four
patients were left in the patient pool when calculating the dose response curve. All of the
MIT patients also received fractionated BNCT (two fractions on consecutive days).
3. Dose response
It is important to look at a dose response curve for the patient data to determine a
more precise correlation between absorbed dose and risk of somnolence. The whole-
brain average dose-response curve of the BNL and MIT patients, after the adjustment
factors have been applied to the BNL patients, can be seen in Figure 31. With the applied
adjustment factors, the MIT and BNL patients can be combined, and with more patients
in the pool of data, the numbers in the dose response curve will be more statistically
significant. Ultimately, by combining patient data from all BNCT institutions,
researchers will be able to determine with good accuracy the risk associated with
administering various whole-brain average doses.
Figure 31 shows the dose response curve for the pooled patient data from BNL and
MIT. In this figure, the x-axis shows whole-brain average weighted dose in Gy-Eq, and
the y-axis shows the fractional probability of developing somnolence. From this plot, the
whole-brain average dose required to produce 50% response in BNCT patients appears to
be about 5.5 Gy-Eq. By administering a whole-brain average dose of just over 6.0 Gy-
Eq, the treatment has a 75% chance of producing somnolence syndrome in the patient.
From this patient data, it is impossible to determine what dose is required to produce
100% response, but it appears to be somewhere between 7 and 8 Gy-Eq. With additional
patients included in the study, a more accurate dose response curve can be calculated.
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VII. Conclusions and Future Work
1. Summary of Conclusions
This thesis makes it possible to pool BNCT patient data from two different clinical
centers. This approach is desirable because of the small number of patients treated at any
one center. By pooling patient data, it becomes easier to determine a cause of the
somnolence endpoint and efficacy of BNCT as a function of dose.
In order to pool BNCT patient data, a number of differences between the BNCT
centers had to be taken into consideration. The differences addressed in this thesis are
tissue definition differences and dosimetry measurements. Once these differences were
evaluated, the patient data were pooled, and a correlation between prescribed patient
whole-brain average dose and the endpoint was determined. From this correlation, the
tolerance of normal brain for somnolence was evaluated, which will be of great use in
future BNCT trials.
While MIT uses a 14N concentration of 2.2% in normal brain tissue, BNL used a 14N
concentration of 1.8% when calculating treatment plans for their respective BNCT
patients. It was found that this difference leads to a difference in peak brain dose of less
than 3%. Therefore, it was decided that this difference is small enough that no correction
factor needed to be applied to the BNL patients because of the '4N difference when
attempting to pool patient data.
Systematic differences in dosimetry techniques were a major hurdle in the
intercomparison process. By breaking down the beam components of the BNL beam,
scaling factors between gamma, '4N, 0°B, and fast neutron dose definitions in
measurements between BNL and MIT were calculated. ' 4N and 10B dose measurements
were found to be 8% lower when measured by MIT in the BNL beam, gamma dose
measurements were found to be 26% lower, and fast neutron dose measurements were
found to be 27% lower (when calculated from in-air measurements). This led to scaling
factors of 0.92, 0.92, 0.74, and 0.73 for the '4N, 10B, gamma, and fast neutron doses,
respectively. These scaling factors were applied to the BNL patient input files, which
were then run through the RTPE treatment planning software, and adjusted peak and
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whole-brain average doses were obtained for all patients treated at BNL. These new peak
and whole-brain average doses were then used, in conjunction with the MIT patient peak
and whole-brain average doses, to determine the correlation between the somnolence
endpoint and dose. It was determined that there appears to be a correlation between
whole-brain average dose and somnolence. When looking at the dose response curve for
the combined MIT and BNL patient data, the probability of producing somnolence
increases to 50% with a whole-brain average dose of about 5.5 Gy-Eq. This tolerance
level is consistent with tissue tolerances previously published [1].
It is also important to note the error on these weighted whole-brain average dose
values. The error on the MIT and BNL measurements were previously calculated, and,
for the weighted dose values, range between about 5% and 15%, depending on the depth
in tissue.
2. Recommendations for Future Work
While this thesis evaluated the differences between two BNCT facility's beams and
normal tissue definition, this research is just the first step to a complete pooling of BNCT
patient data. In order for it to be complete, a few other differences need to be examined
and evaluated. The most predominant difference is the use of different treatment
planning software systems. Differences in treatment planning systems arise mainly from
methods used to calculate dose, but also occur due to differences in the way the patient
geometry is modeled. Therefore, the next step in this process should be a complete
evaluation of treatment-planning software programs.
In order to compare treatment-planning software, it is important to have a common
phantom that can be or has been modeled and simulated using all the software programs.
For instance, the MIT ellipsoidal water-filled phantom has already been run in NCTPlan.
Additionally, access is available to CT scans of the head phantom, and it can thus be run
through RTPE and the output can be compared to that of NCTPlan. Also, if access is
available to MRI scans from a sample patient treated at MIT, this patient can be run in
RTPE, and the treatment plan generated from this program can be compared against that
generated from NCTPlan. In order to compare the treatment planning systems, the
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results from this thesis must be taken into consideration, in order to eliminate the
differences between different facility's measurements. Dosimetry intercomparisons have
already been performed on the clinical epithermal neutron beams at 6 or 7 different
centers [K. Riley, P. Binns, unpublished data].
It is quite important to note that different clinicians were in charge of the follow-up
monitoring of the different BNCT patients, and different clinicians do not evaluate the
somnolence endpoint in the same manner. This presents a significant source of error in
the evaluation of a threshold for somnolence. In the future, it would be best to have a
way for all clinicians to evaluate somnolence to eliminate this error.
Lastly, it will be important to apply a comparison such as the one outlined in this
thesis to other BNCT clinical centers, specifically those using BPA-F. Including
treatment centers that use BSH will necessitate other differences to be taken into
consideration. The more patients that can be combined into one patient pool, the more
accurate results can be obtained. For instance, a more accurate somnolence tolerance
dose could be obtained by including the patients from the other BNCT clinical trials
around the world. By understanding the systematic dosimetry differences between the
BNCT clinical trials, this patient pooling can be done.
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